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ABSTRACT
MODELING GENETIC, NEURAL AND BEHAVIORAL CORRELATES OF SUBSTANCE USE
DISORDERS IN MICE
Julia Katherine Brynildsen
Julie A. Blendy

Over the past several decades, research in animal models has advanced our understanding of
the neurobiological underpinnings of substance use disorders. Influences on drug abuse liability
are broad and multifaceted, and include environmental, genetic and epigenetic factors. A history
of chronic drug use may also induce persistent changes in the brain that contribute to high rates
of relapse.

The collection of studies described herein serves to further our understanding of substance
dependence across genetic, neural and behavioral scales. First, we apply systems approaches to
characterize changes in the functional architecture of the brain following chronic opiate exposure.
We relate these changes to patterns of interregional gene expression and identify regions of the
brain that may drive opiate-induced alterations in the state of the brain. We then examine the
influence of a common genetic variant on cellular physiology and behavior relevant to opiate
abuse liability. Finally, we identify a potential novel therapeutic target for treating symptoms of
withdrawal in a mouse model of nicotine dependence.

This body of work contributes to our understanding of how genetics, behavior, and neural circuitry
contribute to the initiation and maintenance of drug dependence and demonstrates the utility of a
mouse model of nicotine dependence for assessing novel treatment approaches for substance
use disorders.
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CHAPTER 1: General Introduction
A portion of the content in this chapter was originally published in Neuropharmacology.
Brynildsen JK, Blendy JA (2021) Linking the CHRNA5 SNP to drug abuse liability: from circuitry
to cellular mechanisms. Neuropharmacology 186:108480. PMID: 33539855

The etiology of substance use disorders (SUDs) is complex and multifaceted. Genetic and
environmental factors contribute to the initiation of substance abuse, which is maintained by
persistent alterations to neural plasticity. Despite decades of research that have provided insight
into the neurobiology of SUDs, the development of treatment approaches with long-term efficacy
remains a significant challenge.

Rodents engage in a number of behaviors analogous to those associated with human addiction
(1) and are therefore well-suited to investigations into the neurobiology of SUDs. Animal models
enable investigation of the transition from initial drug exposure to chronic drug seeking, which is
generally not possible in human studies. They also offer a controlled environment in which to
study the effects of risk factors for SUDs in isolation, and in which to assess the efficacy of novel
therapeutic approaches.

Modeling the cycle of addiction
The cycle of addiction encompasses the transition from initial drug exposure to chronic drug
taking, which may result in dependence (2). Periods of withdrawal from drug use may be followed
by relapse to drug-seeking behavior (3). Drug taking behavior is thought to consist of three
phases: binge/intoxication, withdrawal/negative affect and preoccupation/anticipation (4). While
initial drug taking is thought to be motivated by rewarding properties of the drug, it has been
argued that the aversive experience of withdrawal may drive continued drug use (4). A number of
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behavioral paradigms have been developed to model distinct components of the addiction cycle
in rodents, including drug reward, drug seeking and taking, dependence, withdrawal and relapse.

Drug reward, escalating intake and dependence
The initiation of drug-taking behavior is motivated by the rewarding properties of the drug. In
rodents, drug reward is commonly assessed via drug self-administration or the conditioned place
preference (CPP) paradigm (5, 6). In the CPP paradigm, animals are conditioned over
consecutive days in which experimenter-administered injections of drug or vehicle are each
paired with one side of a two-or three-chambered apparatus. Animals will thus learn to associate
the receipt of a drug with distinct environmental cues. Relative time spent in the drug-paired side
of the apparatus is considered to be a measure of drug reward. Place preference behavior has
been demonstrated in response to nearly all drugs of abuse (7, 8).

Drug self-administration paradigms are used to model drug reward as well as drug seeking and
escalating intake that are considered hallmarks of SUDs (1). In the self-administration paradigm,
animals learn to perform an operant response in order to receive an infusion of drug. The drug is
usually delivered intravenously, though other routes including inhalation and oral selfadministration are also sometimes used (9). When animals are allowed extended access to drug,
high motivation to take drug and evidence of compulsive use are observed (1). Drug intake that
gradually escalates over time has been observed in response to nicotine, cocaine,
methamphetamine, heroin and alcohol (10-13).

Drug dependence may also by induced via passive administration methods, including
experimenter-administered injections, dissolvable pellets or osmotic minipumps which may be
implanted subcutaneously and release drug continuously. Non-contingent or passive drug
administration does not capture the motivational aspects of drug-seeking behavior that are
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associated with addiction. However, such models permit controlled, consistent dosing and allow
for the study of acute or chronic drug effects in isolation.

Withdrawal
Cessation of chronic drug use is generally accompanied by symptoms of withdrawal which
include both physical and psychological components. The type and duration of withdrawal
symptoms varies depending on the class of drug used and the route of administration (14). In
humans, withdrawal from opiates, alcohol and benzodiazepines may result in physical symptoms
including muscle pains, vomiting, sweating and general discontent. Withdrawal from all drugs of
abuse induces changes in affect, which may include increased anxiety, irritability and anhedonia
(14). While physical symptoms of withdrawal may persist for days to weeks, psychological
symptoms are often more enduring (15-18).

Both affective and physical manifestations of withdrawal have been modeled in rodents (19).
Somatic signs of withdrawal include behaviors such as teeth chattering, tremors, and jumping;
quantification of these signs is often used as a measure of dependence severity (20). Affective
signs of withdrawal may be assessed using rodent models of affective behavior or conditioned
place aversion (CPA) (21, 22). In the CPA paradigm, avoidance of a context that has previously
been paired with the induction of withdrawal is thought to reflect its aversive properties.

Drug Craving, Relapse and Reinstatement
Drug craving may be defined as the incentive motivation to seek a drug that has previously been
consumed (23). Drug craving is shown to increase over the course of withdrawal from chronic
exposure, a phenomenon termed “incubation of craving”. Incubation of craving has been
observed in response to most drugs of abuse, including cocaine, opiates, nicotine,
methamphetamine and alcohol, as well as sucrose (24-26). Incubation of craving has been
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modeled in rodents using both conditioned place preference and self-administration paradigms
(27, 28). This phenomenon suggests that additional neuroadaptations occurring over the course
of withdrawal may contribute to relapse liability.

In humans, relapse to drug use often occurs following periods of abstinence. Relapse to drugseeking may be induced by exposure to a stressor or a drug-associated cue (29, 30), or by acute
re-exposure to the drug itself (31). Incubation of drug craving is also thought to contribute to high
rates of relapse.

In rodent models, relapse is often modeled by a reinstatement paradigm, using drug selfadministration or CPP (32, 33). By definition, reinstatement entails the expression of a learned
behavior after extinction (32). In the self-administration paradigm, saline infusions are substituted
for drug infusions during extinction. Animals learn that the formerly drug-associated cues no
longer predict drug infusions, and eventually cease responding. Reinstatement is often induced
by administering a priming injection of drug, though exposure to a stressor or a drug-associated
cue may also reinstate drug-seeking behavior (34).

In the CPP paradigm, place preference behavior is extinguished by pairing saline injections with
exposure to both sides of the apparatus or by repeated daily test sessions during which the
animal is permitted to explore both sides of the apparatus in the absence of drug (32).
Reinstatement of CPP is then assessed following re-exposure to the drug or another stimulus
(35). The behavior is considered to be reinstated when there is a lack of difference in preference
in the reinstatement test as compared to the initial CPP test (36).
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Addiction circuitry
Distinct neural circuits are implicated in addiction-relevant processes, including drug reward,
dependence, withdrawal and relapse (37). Though different drug classes exert their effects via
divergent molecular mechanisms, circuit-level substrates of drug abuse are largely shared across
drug classes. This section provides a general overview of the brain regions and neural circuitry
implicated in addictive processes.

Drug reward, escalating intake and dependence
The mesolimbic dopamine neurons are part of a well-defined pathway involved in reward
processing. This pathway consists primarily of dopamine fibers arising in the ventral tegmental
area (VTA) and projecting to the nucleus accumbens (NAc). GABAergic interneurons in the VTA
maintain a tonic inhibition over dopaminergic neurons, whereas glutamatergic inputs from the
prefrontal cortex serve to excite these neurons (38-41). The NAc primarily projects to the ventral
pallidum, which plays a role in further processing the drug reward signal (37).

Dopaminergic neurons in the VTA also project to the prefrontal cortex and the extended
amygdala, which includes the central amygdala (CeA), bed nucleus of the stria terminalis (BNST)
and a component of the nucleus accumbens shell (4, 42). Regions of the extended amygdala are
implicated in both drug reward and withdrawal processes. Clinical and preclinical studies have
demonstrated involvement of the CeA in early drug reinforcement via its role in stimulus-reward
learning (43-45).

Reinforcing properties of drugs of abuse lead to escalating drug intake and compulsive use. The
dorsal striatum or caudate putamen (CPu) is recruited during the transition from initial exposure to
compulsive drug-seeking behavior (46). During this transition, drug taking is thought to shift from
voluntary and goal-directed to habitual in nature, and increased dopaminergic transmission shifts
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from the ventral striatum (NAc) to the dorsal striatum (47, 48). At the same time, behavioral
control by the prefrontal cortex may be compromised (48, 49).

Withdrawal
The extended amygdala is also implicated in drug withdrawal. Following the cessation of drug
use, acute withdrawal engages neurochemical systems involved in stress modulation, leading to
increased levels of corticotropin-releasing factor (CRF) in the amygdala (50-52). Altered CRF
signaling in the amygdala is associated with aversive properties of drug withdrawal (50, 53).

Hypofunction of dopaminergic pathways is thought to contribute to negative affective states
associated with protracted withdrawal (54). In accordance with this idea, studies in rodent models
have demonstrated decreased activity of VTA DA neurons and markedly lower levels of
extracellular dopamine in the NAc under withdrawal conditions (55, 56). Reduced DA neuron
activity is associated with despair-like behavior during withdrawal and may be driven by
heightened neuronal activity in the BLA (55).

Drug Craving, Relapse and Reinstatement
Cortical plasticity is implicated in drug craving and reinstatement to drug-seeking behavior.
Individuals with SUDs show hyperfunction of the dorsal medial prefrontal cortex (mPFC) and
hypofunction of the ventral mPFC in response to drug cues (57). Preclinical studies have
demonstrated that projections from the mPFC to the NAc and from the NAc to basolateral
amygdala (BLA) are necessary for reinstatement behavior, which is closely associated with drug
craving (58). The insula also plays a role in craving via its involvement in addiction-related
cognitive control, motivation, and interoception (59, 60).
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Incubation of drug craving over the course of protracted abstinence and exposure to drugassociated cues can each promote reinstatement to drug-seeking. The VTA, NAc and amygdala
are implicated in incubation of craving (25, 27, 61, 62). The basolateral amygdala and
hippocampus play a role in cue-induced reinstatement via their involvement in encoding
conditioned reinforcement and contextual cues, respectively (37).

Systems-level approaches to understanding the neural circuitry of addiction
Given the complex and evolving roles of neurocircuitry in SUDs, addiction may be effectively
characterized as a change in the state of the brain, rather than a pathology of any one particular
circuit or region. Systems-level approaches, including tools derived from graph theory and
network control theory, enable the characterization of whole-brain states as well as interrogation
of the mechanisms driving changes in brain connectivity across time.

Graph theoretic approaches have been widely applied to human neuroimaging data in studies of
SUDs and other disorders (63, 64). Representing the brain as a graph or network entails defining
“nodes”, the discrete components of the networked system, and “edges”, or pairwise connections
between them. In the context of brain connectivity, nodes are often comprised of anatomically- or
functionally-defined regions of the brain, and the edges that connect them may be either
functional, structural or effective in nature (65).

Graph theory metrics are used to define properties of brain networks. These metrics may be used
to characterize the network across scales, ranging from local (node-level) to global (networkwide) (66, 67). For example, at the local level, node degree gives a measure of the number of
edges connected to a given node; on a global scale, the shortest path length is defined as the
minimum number of edges that a signal must traverse from one node to another (68). In the
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context of SUDs, alterations to properties of brain networks defined by graph theory may serve as
biomarkers.

Network control theory is an approach that can be used to identify control points within the brain,
the activity of which can be modulated in order to drive the brain to a particular state or to prevent
the brain from reaching an undesired state. In a proof-of-principle study, it was demonstrated that
network control principles could be used to accurately predict the role of a neuron in motor
function (69). Yan et al. (2017) assessed the impact of laser ablation of individual neurons in the
C. elegans connectome on locomotor behaviors, and demonstrated the essential role of 12
neuronal classes, including one previously uncharacterized neuron. Network control approaches
have since been applied to studying transitions between distinct cognitive states (70, 71). The
study presented in Chapter 2 of this dissertation represents the first application of network control
to understanding changes in the brain that are associated with drug dependence (72).

Genetic influences on substance use disorders
Drug abuse liability is known to have a strong heritable component. Genetics account for as much
as 75% of the risk for nicotine dependence (73, 74), and as much as 80% of the risk for cocaine
and opioid dependence (75). Human genome-wide association studies (GWAS) have identified
common single nucleotide polymorphisms (SNPs) in a number of genes that are linked to drug
addiction (76-78). Chapter 3 of this dissertation focuses on the impact of a common SNP in the
gene CHRNA5 on opioid reward.

The CHRNA5 SNP: Functional implications
A SNP in the gene CHRNA5, which encodes the a5 subunit of the nicotinic acetylcholine receptor
(nAChR), has been repeatedly associated with dependence to multiple substances. a5-
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containing nAChRs are located in regions of the cortex, striatum, hippocampus, thalamus,
amygdala, and midbrain (79-82) and thus are well-positioned to influence the expression of
reward and addictive behaviors.

The SNP rs16969968 in CHRNA5 changes codon 398 from GAT encoding Aspartate (D) to AAT
encoding Asparagine (N) (D398N). The prevalence of the minor allele (A, encoding asparagine)
varies by ethnicity, with a ∼35% frequency among European-origin populations but relatively
uncommon frequency (∼1–5%) among Asian and African populations (83-85).

The non-synonymous change from G to A has been shown to affect calcium permeability and
concentration-response curves of receptor binding to a nicotine agonist in vitro (83). The D398N
SNP was first associated with risk for nicotine dependence over a decade ago (86) , and
numerous studies have since corroborated this finding (85, 87-91). The minor ‘A’ allele has been
linked to smoking heaviness (83, 92-97), pleasurable early smoking experiences (98), delayed
smoking cessation (99) and greater enhancement in cognitive performance following nicotine
exposure (100).

The association of the CHRNA5 SNP with other drugs of abuse has been less well-studied. For
example, studies examining the influence of CHRNA5 D398N on alcohol phenotypes have been
inconclusive. At least one study has identified an association of this SNP with decreased risk for
symptoms of alcohol dependence (88) while others have found no association of the CHRNA5
SNP with alcohol dependence (89, 97, 98, 101). There is a strong correlation between smoking
and alcohol abuse; comorbidity is higher in men compared to women and rates of comorbid
smoking and alcohol use are highest among young smokers (102). However, in one of the largest
GWAS studies of nicotine and alcohol phenotypes, the CHRNA5 SNP was associated with
smoking, specifically cigarettes per day, but not with alcohol use (drinks per week) (89).
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In addition to nicotine and alcohol dependence, human GWAS and candidate SNP studies have
also linked CHRNA5 D398N to risk for dependence to opioids (103, 104) and cocaine (105-107).
It should be noted that in several of these studies, individuals were co-dependent on more than
one drug. Multiple substance dependence diagnoses might limit the ability to detect some
associations and even obscure assessments of risk for various drug classes.

The CHRNA5 SNP: Impact on addiction-relevant circuitry
Collectively, studies on the influence of CHRNA5 D398N on addiction-relevant phenotypes
indicate that this SNP impacts the function of circuitry implicated in distinct addiction-relevant
processes. The SNP is expressed within regions of the brain implicated in drug reward (VTA, SN
and striatum), aversion (MHb-IPN pathway), attention (mPFC) and cue memory (hippocampus).
In the mPFC, α5-containing nAChRs play a critical role in the development of cortical neurons
and in attentional processes (108, 109). In the absence of α5 subunits, the normal developmental
pruning of layer VI mPFC neurons does not occur, and apical dendrites are thus extended in
adulthood. This altered neuronal morphology could change the input received by layer VI mPFC
neurons, and thus impact feedback to the thalamus (109). Further, excitation of layer VI mPFC
pyramidal neurons is dependent on the expression of α5 subunits, and Chrna5 null mice exhibit
disrupted attentional performance in the 5-choice serial reaction time test (108). Within layer II/III
of the mPFC, Chrna5 D398N inhibits the activity of α5 subunit-expressing vasoactive intestinal
polypeptide (VIP) interneurons (Figure 1.1), resulting in behavioral deficits associated with
cognitive impairment (110). These findings may be related to the reduced functional connectivity
between the dorsal anterior cingulate cortex (dACC) and striatum observed in human carriers of
the 398N variant (111), which suggests a reduction in the functional association between circuitry
implicated in attention and reward.
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Identifying the precise location of α5 subunits within the MHb-IPN pathway has been challenging.
Due to co-localization of CHRNA5, CHRNA3 and CHRNB4 within the genome, expression of α5
subunits was initially presumed to overlap with expression of α3 and β4 subunits in the MHb.
However, recent studies have interrogated α5 subunit expression by measuring mRNA or
electrophysiological responses and demonstrated little to no expression of α5 subunits within the
MHb (81, 112). α5-containing nAChRs are located primarily within the rostral subnucleus of the
IPN, on GABAergic neurons that project to the mesopontine raphe and dorsal tegmental area (81,
112-114) (Figure 1.1). These GABAergic neurons may influence reinstatement to nicotine
seeking and avoidance behaviors (114, 115). To our knowledge, no studies have yet investigated
the impact of the Chrna5 SNP on the IPN-mesopontine raphe pathway and relevant phenotypes.
Further work in this area would be informative with respect to the potential modulating role of the
Chrna5 SNP on the serotonergic system.

In the mesolimbic dopamine pathway, α5-containing nAChRs are located on dopaminergic cell
bodies in the VTA, and on terminals in the NAc, where they modulate DA release (Figure 1.1).
Expression of the CHRNA5 398N variant appears to impact the excitability of VTA DA neurons
(116) , which could be relevant to increased nicotine intake observed in mice lacking α5 subunit
expression (117). In Chapter 3 of this dissertation, we present work examining the influence of
Chrna5 D398N on VTA-NAc circuitry in response to morphine.

Sex differences
Vulnerability to substance abuse may be sex-dependent (118-120). This finding has important
implications for the prevention and treatment of substance use disorders. Human studies suggest
that sex differences in SUD liability may be attributable to differences in drug metabolism (121,
122), hormonal influences on the subjective effects of drugs (123, 124), or differences in neuronal
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reactivity to drug-associated cues (125, 126). In general, findings have been inconsistent across
studies.

Studies in rodent models suggest that females acquire drug self-administration more rapidly, put
forth more effort to obtain drug infusions and respond at higher rates during reinstatement tests
than males (127). Rates of drug self-administration may vary depending on the estrous cycle
(128). For example, decreases in heroin self-administration have been observed during proestrus
and are associated with increases in circulating levels of estradiol (128, 129). Due to the paucity
of studies including females, the neurobiology underlying sex differences in drug abuse is not yet
well-understood.

Using animal models to develop novel treatment strategies
Efforts to develop novel treatment approaches for SUDs have focused on alleviating symptoms of
withdrawal (130), interfering with drug-associated memories (131) and diminishing relapse liability
by reducing drug craving (132). With respect to treatment, both predictive and postdictive studies
in animal models can be informative. The former seeks to devise new therapeutics based on
targets identified in preclinical animal studies while the latter involves identifying specific
molecular or behavioral correlates of treatments with demonstrated efficacy in humans. Examples
of successful treatment approaches developed from predictive rodent models include varenicline
and acamprosate. Acamprosate, which is used as a treatment for alcohol use disorder, was
assessed in a clinical trial after it was found to reduce alcohol intake in a rat model (133).
Varenicline is a partial nAChR receptor agonist and effective treatment for nicotine addiction that
was initially shown to inhibit nicotine-induced increases in dopamine release in rodents (134).

Methadone, the first successful pharmacotherapy for addiction, is one example of an addiction
therapeutic that has been postdictively assessed in animal models (135). Methadone was
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originally developed for use as an analgesic (136) and later showed promise as a treatment for
heroin addiction in human patients (137). Subsequent studies in animal models have confirmed
that methadone blocks opiate withdrawal and attenuates relapse to drug seeking (133, 138, 139).

Given the complexity of the behavioral phenomena and circuitry implicated in substance use
disorders, systems-level approaches may also be useful toward the development of effective
treatment approaches. Approaches such as network control theory may prove useful in clinical
applications, for instance by predicting the outcome of cognitive control interventions, applying
transcranial magnetic stimulation to different regions of the brain, or by informing neurofeedback
therapies.

Structure of this dissertation
The overarching goal of this dissertation is to use mouse models of opioid and nicotine
dependence to derive new insights about the etiology and treatment of substance use disorders.
We present a series of studies that seek to understand changes in the state of the brain following
chronic drug exposure, genetic influences on behaviors relevant to substance use disorders, and
potential treatment implications of modulating a molecular target associated with nicotine
dependence and withdrawal.

In Chapter 2, we employ tools from graph theory and network control theory to characterize
changes in the state of the brain following chronic opiate exposure. In Chapter 3, we explore the
impact of a genetic risk factor for substance use disorder on specific behavioral phenotypes and
cellular physiology. In Chapter 4 we investigate the role of a molecular energy sensor, AMPactivated protein kinase (AMPK) in nicotine dependence and withdrawal, with an eye toward
potential therapeutic implications. In Chapter 5, we conclude with an integrative discussion of the
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findings described in this dissertation and future outlook for rodent models of substance use
disorders.
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Figure 1.1. CHRNA5 D398N alters the function of α5 nAChR subunits within addictionrelevant circuitry. CHRNA5 D398N impacts the function α5 nAChR subunits that are expressed
within neural circuits implicated in attention (mPFC), aversion (MHb-IPN), and reward (VTA-NAc).
In layer II/III of the mPFC, α5-containing nAChRs are expressed on vasoactive intestinal
polypeptide (VIP) interneurons that inhibit somatostatin- (SOM) and parvalbumin- (PV)
interneurons; these interneurons inhibit pyramidal cells (111). In layer VI, α5-containing nAChRs
are expressed on pyramidal neurons (81, 112). α5 subunits are also located on GABAergic
neurons in the IPN, where they mediate aversion via inhibitory projections to the mesopontine
raphe (MnR) and laterodorsal tegmental area (LDTg) (81, 112-114), and on the cell bodies and
terminals of DA neurons that project from the VTA to the NAc (114, 115), where they mediate
reward.

15

References
1.

V. Deroche-Gamonet, D. Belin, P. V. Piazza, Evidence for addiction-like behavior in the
rat. Science 305, 1014–1017 (2004).

2.

G. F. Koob, et al., Neurobiological mechanisms in the transition from drug use to drug
dependence. Neurosci Biobehav Rev 27, 739–749 (2004).

3.

J. N. Cleck, J. A. Blendy, Making a bad thing worse: adverse effects of stress on drug
addiction. J Clin Invest 118, 454–461 (2008).

4.

G. F. Koob, M. Le Moal, Plasticity of reward neurocircuitry and the “dark side” of drug
addiction. Nat Neurosci 8, 1442–1444 (2005).

5.

M. T. Bardo, R. A. Bevins, Conditioned place preference: what does it add to our
preclinical understanding of drug reward? Psychopharmacology (Berl) 153, 31–43
(2000).

6.

J. J. Buccafusco, A. J. Prus, J. R. James, J. A. Rosecrans, Conditioned Place
Preference (2009).

7.

D. C. Hoffman, The use of place conditioning in studying the neuropharmacology of drug
reinforcement. Brain Res Bull 23, 373–387 (1989).

8.

M. T. Bardo, J. K. Rowlett, M. J. Harris, Conditioned place preference using opiate and
stimulant drugs: a meta-analysis. Neurosci Biobehav Rev 19, 39–51 (1995).

9.

L. V. Panlilio, S. R. Goldberg, Self-administration of drugs in animals and humans as a
model and an investigative tool. Addiction 102, 1863–1870 (2007).

10.

S. H. Ahmed, G. F. Koob, Transition from moderate to excessive drug intake: change in
hedonic set point. Science 282, 298–300 (1998).

11.

O. Kitamura, S. Wee, S. E. Specio, G. F. Koob, L. Pulvirenti, Escalation of
methamphetamine self-administration in rats: a dose-effect function.
Psychopharmacology (Berl) 186, 48–53 (2006).

12.

L. E. O'Dell, et al., Extended access to nicotine self-administration leads to dependence:
Circadian measures, withdrawal measures, and extinction behavior in rats. J Pharmacol
Exp Ther 320, 180–193 (2007).

13.

L. S. Hwa, et al., Persistent escalation of alcohol drinking in C57BL/6J mice with
intermittent access to 20% ethanol. Alcohol Clin Exp Res 35, 1938–1947 (2011).

14.

R. West, M. Gossop, Overview: a comparison of withdrawal symptoms from different
drug classes. Addiction 89, 1483–1489 (1994).

15.

S. M. Shiffman, The tobacco withdrawal syndrome. NIDA Res Monogr, 158–184 (1979).

16.

F. H. Gawin, Cocaine addiction: psychology and neurophysiology. Science 251, 1580–
1586 (1991).

16

17.

J. Shi, et al., Time-dependent neuroendocrine alterations and drug craving during the
first month of abstinence in heroin addicts. Am J Drug Alcohol Abuse 35, 267–272
(2009).

18.

E. H. Chartoff, H. S. Connery, It's MORe exciting than mu: crosstalk between mu opioid
receptors and glutamatergic transmission in the mesolimbic dopamine system. Front
Pharmacol 5, 116 (2014).

19.

D. H. Malin, P. Goyarzu, Rodent models of nicotine withdrawal syndrome. Handb Exp
Pharmacol 192, 401–434 (2009).

20.

F. Papaleo, A. Contarino, Gender- and morphine dose-linked expression of spontaneous
somatic opiate withdrawal in mice. Behav Brain Res 170, 110–118 (2006).

21.

R. F. Mucha, M. D. Gritti, C. Kim, Aversive properties of opiate withdrawal studied in
rats. NIDA Res Monogr 75, 567–570 (1986).

22.

E. E. Perez, M. De Biasi, Assessment of affective and somatic signs of ethanol
withdrawal in C57BL/6J mice using a short-term ethanol treatment. Alcohol 49, 237–243
(2015).

23.

A. Markou, et al., Animal models of drug craving. Psychopharmacology (Berl) 112, 163–
182 (1993).

24.

J. W. Grimm, B. T. Hope, R. A. Wise, Y. Shaham, Neuroadaptation. Incubation of
cocaine craving after withdrawal. Nature 412, 141–142 (2001).

25.

J. W. Grimm, et al., Time-dependent increases in brain-derived neurotrophic factor
protein levels within the mesolimbic dopamine system after withdrawal from cocaine:
implications for incubation of cocaine craving. J Neurosci 23, 742–747 (2003).

26.

C. L. Pickens, et al., Neurobiology of the incubation of drug craving. Trends Neurosci 34,
411–420 (2011).

27.

Y.-Q. Li, et al., Central amygdala extracellular signal-regulated kinase signaling pathway
is critical to incubation of opiate craving. J Neurosci 28, 13248–13257 (2008).

28.

Y. Sun, G. Chen, K. Zhou, Y. Zhu, A Conditioned Place Preference Protocol for
Measuring Incubation of Craving in Rats. J Vis Exp (2018) https:/doi.org/10.3791/58384.

29.

R. Sinha, How does stress increase risk of drug abuse and relapse?
Psychopharmacology (Berl) 158, 343–359 (2001).

30.

C. P. O'Brien, A. R. Childress, A. T. McLellan, R. Ehrman, Classical conditioning in drugdependent humans. Ann N Y Acad Sci 654, 400–415 (1992).

31.

J. H. Jaffe, N. G. Cascella, K. M. Kumor, M. A. Sherer, Cocaine-induced cocaine
craving. Psychopharmacology (Berl) 97, 59–64 (1989).

32.

Y. Shaham, U. Shalev, L. Lu, H. de Wit, J. Stewart, The reinstatement model of drug
relapse: history, methodology and major findings. Psychopharmacology (Berl) 168, 3–20
(2003).

17

33.

J. M. Bossert, N. J. Marchant, D. J. Calu, Y. Shaham, The reinstatement model of drug
relapse: recent neurobiological findings, emerging research topics, and translational
research. Psychopharmacology (Berl) 229, 453–476 (2013).

34.

U. Shalev, J. W. Grimm, Y. Shaham, Neurobiology of relapse to heroin and cocaine
seeking: a review. Pharmacol Rev 54, 1–42 (2002).

35.

D. Mueller, J. Stewart, Cocaine-induced conditioned place preference: reinstatement by
priming injections of cocaine after extinction. Behav Brain Res 115, 39–47 (2000).

36.

M. A. Aguilar, M. Rodriguez-Arias, J. Miñarro, Neurobiological mechanisms of the
reinstatement of drug-conditioned place preference. Brain Res Rev 59, 253–277 (2009).

37.

G. F. Koob, N. D. Volkow, Neurocircuitry of addiction. Neuropsychopharmacology 35,
217–238 (2010).

38.

S. W. Johnson, R. A. North, Opioids excite dopamine neurons by hyperpolarization of
local interneurons. J Neurosci 12, 483–488 (1992).

39.

P. W. Kalivas, P. Duffy, J. Barrow, Regulation of the mesocorticolimbic dopamine
system by glutamic acid receptor subtypes. J Pharmacol Exp Ther 251, 378–387 (1989).

40.

S. R. Sesack, V. M. Pickel, Prefrontal cortical efferents in the rat synapse on unlabeled
neuronal targets of catecholamine terminals in the nucleus accumbens septi and on
dopamine neurons in the ventral tegmental area. J Comp Neurol 320, 145–160 (1992).

41.

M. T. Taber, S. Das, H. C. Fibiger, Cortical regulation of subcortical dopamine release:
mediation via the ventral tegmental area. J Neurochem 65, 1407–1410 (1995).

42.

R. Spanagel, F. Weiss, The dopamine hypothesis of reward: past and current status.
Trends Neurosci 22, 521–527 (1999).

43.

B. Bie, et al., Upregulation of nerve growth factor in central amygdala increases
sensitivity to opioid reward. Neuropsychopharmacology 37, 2780–2788 (2012).

44.

M. G. Baxter, E. A. Murray, The amygdala and reward. Nat Rev Neurosci 3, 563–573
(2002).

45.

J. A. Gottfried, J. O'Doherty, R. J. Dolan, Encoding predictive reward value in human
amygdala and orbitofrontal cortex. Science 301, 1104–1107 (2003).

46.

B. J. Everitt, et al., Review. Neural mechanisms underlying the vulnerability to develop
compulsive drug-seeking habits and addiction. Philos Trans R Soc Lond B Biol Sci 363,
3125–3135 (2008).

47.

I. Willuhn, L. M. Burgeno, B. J. Everitt, P. E. M. Phillips, Hierarchical recruitment of
phasic dopamine signaling in the striatum during the progression of cocaine use. Proc
Natl Acad Sci U S A 109, 20703–20708 (2012).

48.

B. J. Everitt, T. W. Robbins, From the ventral to the dorsal striatum: devolving views of
their roles in drug addiction. Neurosci Biobehav Rev 37, 1946–1954 (2013).

18

49.

J. D. Jentsch, J. R. Taylor, Impulsivity resulting from frontostriatal dysfunction in drug
abuse: implications for the control of behavior by reward-related stimuli.
Psychopharmacology (Berl) 146, 373–390 (1999).

50.

F. Menzaghi, et al., The role of corticotropin-releasing factor in the anxiogenic effects of
ethanol withdrawal. Ann N Y Acad Sci 739, 176–184 (1994).

51.

R. M. Richter, F. Weiss, In vivo CRF release in rat amygdala is increased during cocaine
withdrawal in self-administering rats. Synapse 32, 254–261 (1999).

52.

G. Koob, M. J. Kreek, Stress, dysregulation of drug reward pathways, and the transition
to drug dependence. Am J Psychiatry 164, 1149–1159 (2007).

53.

S. C. Heinrichs, F. Menzaghi, G. Schulteis, G. F. Koob, L. Stinus, Suppression of
corticotropin-releasing factor in the amygdala attenuates aversive consequences of
morphine withdrawal. Behav Pharmacol 6, 74–80 (1995).

54.

N. D. Volkow, et al., Decreased striatal dopaminergic responsiveness in detoxified
cocaine-dependent subjects. Nature 386, 830–833 (1997).

55.

P. Belujon, N. L. Jakobowski, H. K. Dollish, A. A. Grace, Withdrawal from Acute
Amphetamine Induces an Amygdala-Driven Attenuation of Dopamine Neuron Activity:
Reversal by Ketamine. Neuropsychopharmacology 41, 619–627 (2016).

56.

E. Acquas, G. Di Chiara, Depression of mesolimbic dopamine transmission and
sensitization to morphine during opiate abstinence. J Neurochem 58, 1620–1625 (1992).

57.

M. C. Van den Oever, S. Spijker, A. B. Smit, T. J. De Vries, Prefrontal cortex plasticity
mechanisms in drug seeking and relapse. Neurosci Biobehav Rev 35, 276–284 (2010).

58.

Y. Dong, J. R. Taylor, M. E. Wolf, Y. Shaham, Circuit and Synaptic Plasticity
Mechanisms of Drug Relapse. J Neurosci 37, 10867–10876 (2017).

59.

M. Contreras, F. Ceric, F. Torrealba, Inactivation of the interoceptive insula disrupts drug
craving and malaise induced by lithium. Science 318, 655–658 (2007).

60.

N. H. Naqvi, N. Gaznick, D. Tranel, A. Bechara, The insula: a critical neural substrate for
craving and drug seeking under conflict and risk. Ann N Y Acad Sci 1316, 53–70 (2014).

61.

L. Lu, et al., Central amygdala ERK signaling pathway is critical to incubation of cocaine
craving. Nat Neurosci 8, 212–219 (2005).

62.

K. L. Conrad, et al., Formation of accumbens GluR2-lacking AMPA receptors mediates
incubation of cocaine craving. Nature 454, 118–121 (2008).

63.

A. Fornito, A. Zalesky, M. Breakspear, Graph analysis of the human connectome:
promise, progress, and pitfalls. Neuroimage 80, 426–444 (2013).

64.

M. N. Hallquist, F. G. Hillary, Graph theory approaches to functional network
organization in brain disorders: A critique for a brave new small-world. Netw Neurosci 3,
1–26 (2019).

19

65.

K. J. Friston, Functional and effective connectivity in neuroimaging: A synthesis. Human
Brain Mapping 2, 56–78 (1994).

66.

M. Rubinov, O. Sporns, Complex network measures of brain connectivity: uses and
interpretations. Neuroimage 52, 1059–1069 (2010).

67.

O. Sporns, Graph theory methods: applications in brain networks. Dialogues Clin
Neurosci 20, 111–121 (2018).

68.

A. Avena-Koenigsberger, B. Misic, O. Sporns, Communication dynamics in complex
brain networks. Nat Rev Neurosci 19, 17–33 (2017).

69.

G. Yan, et al., Network control principles predict neuron function in the Caenorhabditis
elegans connectome. Nature 550, 519–523 (2017).

70.

Z. Cui, et al., Optimization of energy state transition trajectory supports the development
of executive function during youth. Elife 9, 17 (2020).

71.

T. M. Karrer, et al., A practical guide to methodological considerations in the
controllability of structural brain networks. J Neural Eng 17, 026031 (2020).

72.

J. K. Brynildsen, et al., Gene coexpression patterns predict opiate-induced brain-state
transitions. Proc Natl Acad Sci U S A 117, 19556–19565 (2020).

73.

K. S. Kendler, et al., A population-based twin study in women of smoking initiation and
nicotine dependence. Psychol Med 29, 299–308 (1999).

74.

J. M. Vink, G. Willemsen, D. I. Boomsma, Heritability of smoking initiation and nicotine
dependence. Behav Genet 35, 397–406 (2005).

75.

D. Goldman, G. Oroszi, F. Ducci, The genetics of addictions: uncovering the genes. Nat
Rev Genet 6, 521–532 (2005).

76.

K. P. Jensen, A Review of Genome-Wide Association Studies of Stimulant and Opioid
Use Disorders. Mol Neuropsychiatry 2, 37–45 (2016).

77.

R. C. Crist, T.-K. Clarke, W. H. Berrettini, Pharmacogenetics of Opioid Use Disorder
Treatment. CNS Drugs 32, 305–320 (2018).

78.

W. Berrettini, A brief review of the genetics and pharmacogenetics of opioid use
disorders. Dialogues Clin Neurosci 19, 229–236 (2017).

79.

W. Berrettini, et al., Alpha-5/alpha-3 nicotinic receptor subunit alleles increase risk for
heavy smoking. Mol Psychiatry 13, 368–373 (2008).

80.

A. Flora, et al., Neuronal and extraneuronal expression and regulation of the human
alpha5 nicotinic receptor subunit gene. J Neurochem 75, 18–27 (2000).

81.

Y.-W. A. Hsu, et al., Medial habenula output circuit mediated by α5 nicotinic receptorexpressing GABAergic neurons in the interpeduncular nucleus. J Neurosci 33, 18022–
18035 (2013).

20

82.

E. Wada, D. McKinnon, S. Heinemann, J. Patrick, L. W. Swanson, The distribution of
mRNA encoded by a new member of the neuronal nicotinic acetylcholine receptor gene
family (alpha 5) in the rat central nervous system. Brain Res 526, 45–53 (1990).

83.

L. J. Bierut, et al., Variants in nicotinic receptors and risk for nicotine dependence. Am J
Psychiatry 165, 1163–1171 (2008).

84.

M. D. Li, et al., Associations of variants in CHRNA5/A3/B4 gene cluster with smoking
behaviors in a Korean population. PLoS One 5, e12183 (2010).

85.

N. L. Saccone, et al., The CHRNA5-CHRNA3-CHRNB4 nicotinic receptor subunit gene
cluster affects risk for nicotine dependence in African-Americans and in EuropeanAmericans. Cancer Res 69, 6848–6856 (2009).

86.

S. F. Saccone, et al., Cholinergic nicotinic receptor genes implicated in a nicotine
dependence association study targeting 348 candidate genes with 3713 SNPs. Hum Mol
Genet 16, 36–49 (2007).

87.

L.-S. Chen, et al., Interplay of Genetic Risk Factors and Parent Monitoring in Risk for
Nicotine Dependence. Addiction 104, 1731–1740 (2009).

88.

X. Chen, et al., Variants in nicotinic acetylcholine receptors alpha5 and alpha3 increase
risks to nicotine dependence. Am J Med Genet B Neuropsychiatr Genet 150B, 926–933
(2009).

89.

M. Liu, et al., Association studies of up to 1.2 million individuals yield new insights into
the genetic etiology of tobacco and alcohol use. Nat Genet 51, 237–244 (2019).

90.

N. L. Saccone, et al., Multiple distinct risk loci for nicotine dependence identified by
dense coverage of the complete family of nicotinic receptor subunit (CHRN) genes. Am
J Med Genet B Neuropsychiatr Genet 150B, 453–466 (2009).

91.

G. Winterer, et al., Risk gene variants for nicotine dependence in the CHRNA5CHRNA3-CHRNB4 cluster are associated with cognitive performance. Am J Med Genet
B Neuropsychiatr Genet 153B, 1448–1458 (2010).

92.

M. S. Conlon, M. A. Bewick, Single nucleotide polymorphisms in CHRNA5 rs16969968,
CHRNA3 rs578776, and LOC123688 rs8034191 are associated with heaviness of
smoking in women in Northeastern Ontario, Canada. Nicotine Tob Res 13, 1076–1083
(2011).

93.

J. Z. Liu, et al., Meta-analysis and imputation refines the association of 15q25 with
smoking quantity. Nat Genet 42, 436–440 (2010).

94.

R. Pérez-Morales, et al., CHRNA3 rs1051730 and CHRNA5 rs16969968 polymorphisms
are associated with heavy smoking, lung cancer, and chronic obstructive pulmonary
disease in a mexican population. Ann Hum Genet 82, 415–424 (2018).

95.

N. L. Saccone, et al., Multiple independent loci at chromosome 15q25.1 affect smoking
quantity: a meta-analysis and comparison with lung cancer and COPD. PLoS Genet 6,
e1001053 (2010).

21

96.

V. L. Stevens, et al., Nicotinic receptor gene variants influence susceptibility to heavy
smoking. Cancer Epidemiol Biomarkers Prev 17, 3517–3525 (2008).

97.

J. Hällfors, et al., Scrutiny of the CHRNA5-CHRNA3-CHRNB4 smoking behavior locus
reveals a novel association with alcohol use in a Finnish population based study. Int J
Mol Epidemiol Genet 4, 109–119 (2013).

98.

R. Sherva, et al., Association of a single nucleotide polymorphism in neuronal
acetylcholine receptor subunit alpha 5 (CHRNA5) with smoking status and with
“pleasurable buzz” during early experimentation with smoking. Addiction 103, 1544–
1552 (2008).

99.

L.-S. Chen, et al., CHRNA5 risk variant predicts delayed smoking cessation and earlier
lung cancer diagnosis--a meta-analysis. J Natl Cancer Inst 107 (2015).

100.

K. P. Jensen, et al., A CHRNA5 Smoking Risk Variant Decreases the Aversive Effects of
Nicotine in Humans. Neuropsychopharmacology 40, 2813–2821 (2015).

101.

J. C. Wang, et al., Genetic variation in the CHRNA5 gene affects mRNA levels and is
associated with risk for alcohol dependence. Mol Psychiatry 14, 501–510 (2009).

102.

D. E. Falk, H.-Y. Yi, S. Hiller-Sturmhöfel, An epidemiologic analysis of co-occurring
alcohol and tobacco use and disorders: findings from the National Epidemiologic Survey
on Alcohol and Related Conditions. Alcohol Res Health 29, 162–171 (2006).

103.

K. Curtis, et al., Increased habenular connectivity in opioid users is associated with an
α5 subunit nicotinic receptor genetic variant. Am J Addict 26, 751–759 (2017).

104.

P. M. Erlich, et al., Nicotinic acetylcholine receptor genes on chromosome 15q25.1 are
associated with nicotine and opioid dependence severity. Hum Genet 128, 491–499
(2010).

105.

A. P. Aroche, et al., Association of CHRNA5 Gene Variants with Crack Cocaine
Addiction. Neuromolecular Med 22, 384–390 (2020).

106.

R. A. Grucza, et al., A risk allele for nicotine dependence in CHRNA5 is a protective
allele for cocaine dependence. Biol Psychiatry 64, 922–929 (2008).

107.

R. Sherva, et al., Variation in nicotinic acetylcholine receptor genes is associated with
multiple substance dependence phenotypes. Neuropsychopharmacology 35, 1921–1931
(2010).

108.

C. D. C. Bailey, M. De Biasi, P. J. Fletcher, E. K. Lambe, The nicotinic acetylcholine
receptor alpha5 subunit plays a key role in attention circuitry and accuracy. J Neurosci
30, 9241–9252 (2010).

109.

C. D. C. Bailey, N. C. Alves, R. Nashmi, M. De Biasi, E. K. Lambe, Nicotinic α5 subunits
drive developmental changes in the activation and morphology of prefrontal cortex layer
VI neurons. Biol Psychiatry 71, 120–128 (2012).

110.

F. Koukouli, et al., Nicotine reverses hypofrontality in animal models of addiction and
schizophrenia. Nat Med 23, 347–354 (2017).

22

111.

L. E. Hong, et al., A genetically modulated, intrinsic cingulate circuit supports human
nicotine addiction. Proc Natl Acad Sci U S A 107, 13509–13514 (2010).

112.

G. Morton, et al., Chrna5-Expressing Neurons in the Interpeduncular Nucleus Mediate
Aversion Primed by Prior Stimulation or Nicotine Exposure. J Neurosci 38, 6900–6920
(2018).

113.

L. A. Quina, J. Harris, H. Zeng, E. E. Turner, Specific connections of the interpeduncular
subnuclei reveal distinct components of the habenulopeduncular pathway. J Comp
Neurol 525, 2632–2656 (2017).

114.

S. L. Wolfman, et al., Nicotine aversion is mediated by GABAergic interpeduncular
nucleus inputs to laterodorsal tegmentum. Nat Commun 9, 2710–11 (2018).

115.

B. Forget, et al., A Human Polymorphism in CHRNA5 Is Linked to Relapse to Nicotine
Seeking in Transgenic Rats. Curr Biol 28, 3244–3253.e7 (2018).

116.

E. N. Oni, et al., Increased nicotine response in iPSC-derived human neurons carrying
the CHRNA5 N398 allele. Sci Rep 6, 34341–11 (2016).

117.

C. Morel, et al., Nicotine consumption is regulated by a human polymorphism in
dopamine neurons. Mol Psychiatry 19, 930–936 (2014).

118.

S. F. Greenfield, G. O'Leary, Sex differences in substance use disorders. (2002).

119.

R. K. McHugh, V. R. Votaw, D. E. Sugarman, S. F. Greenfield, Sex and gender
differences in substance use disorders. Clin Psychol Rev 66, 12–23 (2018).

120.

J. A. Quigley, et al., Sex differences in vulnerability to addiction. Neuropharmacology 58,
108491 (2021).

121.

E. Baraona, et al., Gender differences in pharmacokinetics of alcohol. Alcohol Clin Exp
Res 25, 502–507 (2001).

122.

N. L. Benowitz, C. N. Lessov-Schlaggar, G. E. Swan, P. Jacob, Female sex and oral
contraceptive use accelerate nicotine metabolism. Clin Pharmacol Ther 79, 480–488
(2006).

123.

L. Holdstock, H. de Wit, Effects of ethanol at four phases of the menstrual cycle.
Psychopharmacology (Berl) 150, 374–382 (2000).

124.

S. M. Evans, M. Haney, R. W. Foltin, The effects of smoked cocaine during the follicular
and luteal phases of the menstrual cycle in women. Psychopharmacology (Berl) 159,
397–406 (2002).

125.

N. D. Volkow, et al., Reduced metabolism in brain “control networks” following cocainecues exposure in female cocaine abusers. PLoS One 6, e16573 (2011).

126.

D. Seo, et al., Sex differences in neural responses to stress and alcohol context cues.
Human Brain Mapping 32, 1998–2013 (2011).

23

127.

W. J. Lynch, Sex differences in vulnerability to drug self-administration. Exp Clin
Psychopharmacol 14, 34–41 (2006).

128.

R. T. Lacy, J. C. Strickland, M. A. Feinstein, A. M. Robinson, M. A. Smith, The effects of
sex, estrous cycle, and social contact on cocaine and heroin self-administration in rats.
Psychopharmacology (Berl) 233, 3201–3210 (2016).

129.

M. A. Smith, et al., Modulation of heroin intake by ovarian hormones in gonadectomized
and intact female rats. Psychopharmacology (Berl) 76, 235–10 (2021).

130.

J. V. Pergolizzi, R. B. Raffa, M. H. Rosenblatt, Opioid withdrawal symptoms, a
consequence of chronic opioid use and opioid use disorder: Current understanding and
approaches to management. J Clin Pharm Ther 45, 892–903 (2020).

131.

J. L. C. Lee, P. Di Ciano, K. L. Thomas, B. J. Everitt, Disrupting reconsolidation of drug
memories reduces cocaine-seeking behavior. Neuron 47, 795–801 (2005).

132.

C. P. O'Brien, Anticraving medications for relapse prevention: a possible new class of
psychoactive medications. Am J Psychiatry 162, 1423–1431 (2005).

133.

R. C. Pierce, C. P. O'Brien, P. J. Kenny, L. J. M. J. Vanderschuren, Rational
development of addiction pharmacotherapies: successes, failures, and prospects. Cold
Spring Harb Perspect Med 2, a012880–a012880 (2012).

134.

J. W. Coe, et al., Varenicline: an alpha4beta2 nicotinic receptor partial agonist for
smoking cessation. J Med Chem 48, 3474–3477 (2005).

135.

M. Field, I. Kersbergen, Are animal models of addiction useful? Addiction 115, 6–12
(2020).

136.

R. H. THORP, E. WALTON, P. OFNER, Analgesic activity in compounds related to
amidone. Nature 159, 679–680 (1947).

137.

V. P. DOLE, M. NYSWANDER, A MEDICAL TREATMENT FOR DIACETYLMORPHINE
(HEROIN) ADDICTION. A CLINICAL TRIAL WITH METHADONE HYDROCHLORIDE.
JAMA 193, 646–650 (1965).

138.

P. G. Goode, An implanted reservoir of morphine solution for rapid induction of physical
dependence in rats. Br J Pharmacol 41, 558–566 (1971).

139.

B. E. Jones, J. A. Prada, Effects of methadone and morphine maintenance on drugseeking behavior in the dog. Psychopharmacology (Berl) 54, 109–112 (1977).

24

CHAPTER 2: Gene coexpression patterns predict opiate-induced brain-state transitions
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Abstract
Opioid addiction is a chronic, relapsing disorder associated with persistent changes in brain
plasticity. Reconfiguration of neuronal connectivity may explain heightened abuse liability in
individuals with a history of chronic drug exposure. To characterize network-level changes in
neuronal activity induced by chronic opiate exposure, we compared FOS expression in mice that
are morphine-naïve, morphine-dependent, or have undergone 4 weeks of withdrawal from
chronic morphine exposure, relative to saline-exposed controls. Pairwise interregional
correlations in FOS expression data were used to construct network models that reveal a
persistent reduction in connectivity strength following opiate dependence. Further, we
demonstrate that basal gene expression patterns are predictive of changes in FOS correlation
networks in the morphine-dependent state. Finally, we determine that regions of the
hippocampus, striatum and midbrain are most influential in driving transitions between opiatenaïve and opiate-dependent brain states using a control theoretic approach. This study provides
a framework for predicting the influence of specific therapeutic interventions on the state of the
opiate-dependent brain.

Keywords: opioid dependence, network analysis, mice, graph theory, control theory
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Significance Statement
Persistent alterations to neural circuitry may help to explain why opiate abuse liability is higher
amongst individuals with a history of chronic exposure. In this study, we employ a unique
combination of computational approaches to understand how opiate-induced reorganization of
network connectivity is supported by transcriptional and structural features of the brain. We
identify a persistent reduction in FOS correlation network strength following opiate dependence
and determine that correlated gene expression is predictive of opiate-induced changes in network
connectivity. Further, we identify brain regions that influence the transition between opiate-naïve
and opiate-dependent states. These findings establish a link between gene expression and
changes in brain connectivity in response to opioids.
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Introduction
Drug dependence and relapse liability are thought to be supported by lasting alterations in neural
circuitry. In light of the ongoing opioid epidemic in the United States, there is growing interest in
connectivity-based approaches to understand the influence of opioid use disorder (OUD) on the
brain’s responsiveness to opiates and opiate-related cues (1). Such approaches hold promise for
identifying biomarkers for OUD and for predicting treatment response.

Human neuroimaging studies have provided valuable insight into the neural correlates of OUD (14). However, such investigations are challenged by the marked individual variability in
polysubstance abuse and duration of use. In contrast, rodent models offer a controlled
environment in which to study the mechanisms of chronic opiate effects on the brain. In the
interest of identifying brain regions that are critically involved in drug reward, dependence, and
withdrawal, expression of the immediate early gene c-Fos has been widely used in preclinical
rodent models as a marker for neuronal activity. Induction of c-Fos occurs following both acute
and chronic exposure to drugs of abuse and during withdrawal, and its expression is correlated
with drug-induced behavioral changes including locomotor sensitization, conditioned place
preference (CPP), and conditioned place aversion (CPA) (5-7).

Four weeks of abstinence from chronic morphine exposure prior to conditioning has been shown
to increase morphine CPP in rats, suggesting that rewarding properties of the drug are enhanced
following protracted withdrawal (8). This enhanced preference is also associated with increased
FOS expression in the cingulate cortex (Cg), nucleus accumbens (NAc), bed nucleus of the stria
terminalis (BNST), and central and basolateral amygdala (CeA and BLA) (8). Induction of FOS
protein expression in the NAc core and shell, dorsal striatum, ventral pallidum, lateral
hypothalamus, and cortical regions following acute morphine has also been shown in rodent
models (9), with the NAc and striatum displaying the most consistent activation across studies.
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Analysis of FOS expression in rodent models has been critical for identifying individual brain
regions associated with opioid exposure. However, OUD is a complex disease that will require a
holistic rather than reductionist approach to fully appreciate its biological underpinnings. Studying
the activity of individual regions in isolation ignores higher-order relationships between regions
that form networks, in which individual brain regions may be represented as nodes, and their
functional associations may be represented as edges (10, 11). Dynamics on these networks can
be studied mathematically using tools from network control theory (12).

The basic premise to be investigated in the current study is that chronic exposure to opioids
causes changes in FOS correlation networks, which we define as interregional correlations in
neuronal activation across subjects. We hypothesize that these changes occur in key areas of the
brain that may pre-dispose an individual to increased drug-seeking behavior. To this end, we
apply a novel combination of computational approaches (graph theory and network control
theory) to 1) define characteristics of FOS correlation networks associated with opioid
dependence, 2) characterize gene expression patterns associated with changes in FOS
correlation network connectivity induced by opioid dependence, and 3) identify brain regions that
are most influential in the transition from an opiate-naïve to an opiate-dependent brain state
(overview of design; Fig. 2.1). The analysis of complex networks with respect to OUD could shed
light on the causes and mechanisms of the disease and provide compelling targets for
therapeutic interventions.

Results
Acute morphine increases FOS expression in a state-dependent manner
To test the hypothesis that dependence alters neuronal activity in response to morphine, we
administered an acute, rewarding dose of morphine (10 mg/kg) to mice in three states: drugnaïve, 24 h after chronic exposure (at which time dependence has been established, as
evidenced by increased somatic signs of withdrawal shown in SI Appendix, Fig. S2.1), and 4
weeks after chronic exposure. FOS expression was quantified in each of these three treatment
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groups and in a saline-injected control group within 19 brain regions of interest. All FOS
expression values were normalized to the mean FOS expression in saline-injected controls to
compute fold change. Analysis of fold change in FOS expression by two-way ANOVA revealed
significant main effects of brain region (F18,570 = 19.52, p < 0.0001) and treatment (F3,570 = 104.0, p
< 0.0001), and a significant region × treatment interaction (F54,570 = 4.493, p < 0.0001) (Fig. 2.2).

We performed Bonferroni post-hoc tests over all 19 families of 6 pairwise comparisons for each
brain region and set the statistical threshold for a significant difference in FOS expression
between any two treatment groups to p < 0.05. We observed state-dependent increases relative
to saline controls within 12 brain regions: the dACC, vACC, AId, Cla, CPu, NAc, BNST, BLA,
CeA, LHb, SNc and VTA. Mice in all morphine-treated groups showed elevated FOS expression
in the dACC, Cla, CPu, NAc, BNST and BLA relative to saline-treated controls. In the BLA, FOS
expression was also significantly elevated at 24 h compared to in the naïve state. In the CPu,
FOS expression was also significantly greater after 4 weeks compared to in the naïve state. In
the dACC, FOS expression was significantly greater in the naïve condition compared to 24 h, and
in both the dACC and VTA, FOS expression was significantly elevated 4 weeks after chronic
exposure relative to all other conditions. FOS expression increased only in mice with prior chronic
exposure in the AId (at 24 h), in the LHb and SNc (at 4 weeks), and in the CeA (at 24 h and 4
weeks). In the vACC, FOS expression increased only in the naïve and 4 week groups, and the 4
week group showed significantly higher expression than the 24 h group. FOS expression was not
significantly elevated in the AIv, VP, DG, MHb, PVT, PAG, or SNr in any treatment group. Thus,
neuronal activity in response to an acute dose of morphine is significantly different depending on
brain state.

Chronic opiate exposure alters network connectivity
After identifying region-specific effects of morphine dependence on FOS expression, we next
sought to characterize network-level changes in interregional FOS correlation networks across
brain regions. We generated FOS correlation networks based on pairwise interregional
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correlations in FOS expression across mice. Interregional Pearson’s correlation coefficients were
calculated based on fold change in FOS expression (relative to saline) in 19 brain regions (Fig.
2.3a). Each brain region is represented as a node in the network, and correlations in FOS
expression are represented as edges which are weighted according to the strength of the
correlation (Fig. 2.3c). A one-way ANOVA of Fisher’s z-transformed positive Pearson’s r values
revealed a significant reduction in mean correlation strength 24 h after chronic exposure
compared to in the drug-naïve state, and this reduction is maintained 4 weeks after chronic
exposure (Fig. 2.3b). These data indicate that opioid dependence induces a reduction in
functional coupling between brain regions that persists across time, as reflected by the striking
difference in connectivity between states (Fig. 2.3c). We observed the same results when using
Spearman correlations instead of Pearson correlations (SI Appendix, Fig. S2.2).

A common objective of graph theory approaches to network analysis is to identify nodes that are
relatively “central” within the network, which may suggest an important role in information flow
between other nodes (13, 14). Here, we used two centrality measures to assess local connectivity
within the global context of our networks: weighted degree and betweenness centrality. Weighted
degree refers to the sum of edges connected to a given node, weighted by their strength (15).
Nodes with high degree are often referred to as network hubs, and may strongly influence the
network’s function (13, 14). Betweenness centrality refers to the number of shortest paths
between other nodes that a given node intersects (13). In the context of this work, betweenness
centrality reflects the extent to which one brain region acts as an intermediary between other
brain regions.

Analysis by two-sample Kolmogorov–Smirnov test revealed that relative to the naïve state,
networks significantly differed in distributions of weighted degree at 24 h (D36 = 0.6316, p =
0.0021) and 4 weeks (D36 = 0.5263, p = 0.028) after chronic morphine exposure (Fig. 2.3d).
There was no change in weighted degree distribution between 24 h and 4 weeks (D36 = 0.3158, p
= 0.92). To examine region-specific changes in weighted degree across conditions, we performed
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a two-way ANOVA and identified significant main effects of region (F5,39 = 7.743, p < 0.0001) and
treatment (F2,39 = 23.95, p < 0.0001) and a significant region × treatment interaction (F10,39 =
4.161, p = 0.0006). In regions of the midbrain, weighted degree was significantly reduced at 24 h
after chronic exposure compared to in the naïve and protracted withdrawal states (Bonferronicorrected p < 0.0001). Nonsignificant reductions in weighted degree were observed across all
other region groups in the 24 h and 4 week states relative to the naïve state (SI Appendix, Fig.
S2.3a). Distributions of weighted betweenness centrality did not differ across states (D36 ≤
0.3158, p ≥ 0.90) (Fig. 2.3e), and region-specific analysis by two-way ANOVA revealed a
significant main effect of region (F5,39 = 2.523, p = 0.0451) but no effect of treatment (F2,39 =
0.6490, p = 0.5281) and no region × treatment interaction(F10,39 = 1.144, p = 0.3562) (SI
Appendix, Fig. S2.3b). Taken together, these findings suggest that opioid dependence alters the
functional architecture of the brain by modulating the strength of connections between pairs of
regions, particularly within the midbrain, but not by altering the tendency for brain regions to
mediate connections between other regions.

Basal gene expression patterns predict change in FOS correlation networks following opioid
dependence
We next sought to identify a transcriptional basis for opiate-induced changes in FOS correlation
networks. We used transcriptomic data recently released by the Allen Institute, which allows for
the spatial resolution of gene expression across brain regions. This dataset was used to examine
correlated gene expression patterns across 19,616 genes within our 19 brain regions of interest.
We defined gene coexpression as spatially-corrected pairwise correlations in expression across
all genes between every pair of brain regions. We then performed a linear regression of mean
gene coexpression per brain region with change in weighted degree from the drug-naïve to the 24
h state. We hypothesized that basal gene expression may play a role in how certain brain regions
are functionally connected. Of interest, we identified a significant, positive linear relationship
between basal gene coexpression and changes in FOS correlation networks that results following
chronic opioid exposure (Fig. 2.4a). Specifically, we observed stronger gene coexpression among
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pairs of brain regions that show increased connection strength after opioid exposure, compared
to those that show decreased connection strength. Thus, basal gene coexpression patterns are
predictive of changes in FOS correlation networks following chronic opioid exposure.

To identify specific genes that contribute significantly to the higher coexpression among pairs of
regions that show increased connection strength compared with those that show decreased
connection strength (Fig. 2.4b) we calculated a gene coexpression contribution (GCC) score for
each gene (16), which yields a t-statistic score and p value for each gene. After applying a false
discovery rate (FDR) correction (q < 0.05) for multiple comparisons across the 19,616 tests, we
identified 2,775 genes that significantly contribute to higher gene coexpression amongst brain
region pairs that show increased connectivity compared to brain region pairs that show
decreased connectivity following opioid dependence. In order to appreciate the biological
significance of these genes, we used Ingenuity Pathway Analysis software to functionally
annotate genes that contribute to stronger transcriptional coupling between regions that show
increased connectivity following opioid dependence. Among the most significantly-associated
pathways were Synaptic Long Term Potentiation, Synaptogenesis Signaling Pathway, Integrin
Signaling, and Reelin Signaling in Neurons (Table 2.1). These findings are in line with the notion
that drugs of abuse alter synaptic transmission, which is reflected by changes in FOS correlation
networks.

Network Control
Drug dependence is understood to coincide with a change in the state of the brain. A major
challenge in the treatment of substance use disorders is determining how to restore the brain to
its former state (17). Reaching this goal will require an understanding not only of how neural
circuitry is altered by drug dependence, but of the molecular and physiological mechanisms that
drive persistent circuitry alterations in the brain.
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In the interest of identifying potential therapeutic targets for OUD, we sought to identify brain
regions that drive network-level changes in neuronal activity. To this end, we employed a network
control theory approach. Network control is an emerging approach in systems engineering with
marked utility in neuroscience (18-23). Control in the brain may be exerted internally (for
example, via cognitive control) or externally (for example, via stimulation). In recent years, control
theory approaches have been applied to examine cognitively relevant brain state transitions
observed in human functional magnetic resonance imaging data (19), (24-26).

Here, we used network control theory to explore how OUD-dependent changes in FOS
expression may be mediated by the topology of axonal connections in the brain. The approach
posits that transitions between states are constrained by the energy required to transmute one
state into another, allowing activity to spread solely through known structural interregional links.
Specifically, we computed the minimum whole-brain input energy required to transition between
brain activity patterns associated with different opioid-dependence states. Brain activity is
represented by fold change in FOS expression vectors and the brain network defined by
interregional axonal connection strength obtained from the Allen Mouse Brain Atlas (27). In
principle, this approach measures the ease with which the brain can transition from a drug-naive
to a drug-dependent activity state, and from a drug-dependent to a protracted withdrawal activity
state (Fig. 2.5b), given the constraints imposed by the topology of axonal connections between
the measured regions. Our model does not distinguish the drivers of such transitions, which in
this case are likely a combination of internal neuronal dynamics and external inputs (i.e., opiate
exposure).

For each state transition, the minimum control energy was first calculated under full control
(meaning external input can be delivered to all regions), and then recalculated following
suppression of each region (external input can be delivered to all regions except the suppressed
region). This analysis determines the increase in minimum control energy induced by the removal
of each brain region which, in essence, quantifies the relative influence of each brain region in the
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transition from one state to another. Relative to all other regions in the network, we identified 9
brain regions that influence minimum control energy for the transition from a naïve state to 24 h
“dependent” state: the vACC, CPu, NAc, VP, BNST, CeA, DG, PAG, and SNr (Table 2.2). These
same regions, with the addition of the LHb and VTA, influence minimum control energy for the
transition from the 24 h “dependent” state to the 4 weeks protracted withdrawal state. The CPu,
DG, and PAG stand out in the transition from naïve to dependent state, while the PAG and SNr
most strongly influence minimum control energy for the transition from the 24 h to 4 week states
(Fig. 2.5b). In contrast, cortical and thalamic regions do not appear to significantly impact either
state transition. Together, these findings indicate that regions of the hippocampus, striatum, and
midbrain may be topologically positioned to facilitate easy transitions between activity patterns
associated with different states of opioid dependence.

Discussion
Here we sought to determine the impact of opiate dependence on FOS correlation network
connectivity, to identify gene coexpression patterns that predict opiate-induced changes in FOS
correlation networks, and to determine the relative contributions of key brain regions to the
minimum control energy required to drive the brain from one functional state of dependence to
another. To this end, we describe network analyses of interregional FOS expression in 19 brain
regions in three states: opiate-naïve, 24 h after chronic opiate exposure, and 4 weeks after
chronic opiate exposure. Morphine is known to induce FOS expression throughout the brain;
however, our data demonstrates that the FOS response varies in a state-dependent manner.
Pairwise interregional correlations in FOS expression were used to generate weighted networks,
which reflect a significant reduction in mean positive correlation strength following chronic
morphine exposure, suggesting that the strength of FOS correlation networks between brain
regions is state-dependent. Finally, we show that axonal connectivity between regions of the
striatum, midbrain, and hippocampus is critical for low-energy state transitions between functional
states of opioid dependence. These data support the notion that repeated exposure to addictive
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drugs induces reorganization of neural circuitry that may underlie behaviors characteristic of
addiction.

To capture the relationship between basal transcriptional coupling patterns and opiate-induced
changes in FOS correlation networks, we examined gene coexpression patterns between all
brain regions included in our study. Pathway analysis revealed that genes implicated in synaptic
LTP, synaptogenesis, and reelin signaling were among the most significantly associated with
increased FOS correlation networks following chronic opiate exposure (Table 1). Many drugs of
abuse, including opioids, induce synaptic plasticity, suggesting that this type of neuroadaptation
may be a common mechanism underlying the development of substance use disorders (28-30).
Moreover, polymorphisms in genes associated with synaptic plasticity have been associated with
vulnerability to drug addiction (31, 32). Our data indicates that coordinated expression of genes
implicated in synaptic plasticity may predispose pairs of brain regions to increased FOS
correlation networks induced by opiate dependence.

While graph theory metrics offer valuable approaches for characterizing connectivity properties,
network control theory posits a mechanism for how inter-regional interactions give rise to statedependent neural activity (18). Network control theory explains how a network may be driven to a
particular activity state by modulating external inputs (18, 19). Here, we calculated the minimum
input energy required to transition between brain activity patterns associated with drug-naïve and
drug-dependent states. In the context of our work, opiate exposure is a major known external
input, and we identify brain regions whose structural connectivity strongly influence the magnitude
of input required to drive the brain into opiate-dependent activity states.

With respect to drug addiction, the brain and associated cellular and molecular mechanisms may
adapt to chronic drug exposure differently depending on the individual. Indeed, epidemiological
and clinical research have shown that most individuals who use drugs do not develop
dependence. While environmental stressors and genetic factors can contribute to an individual's
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propensity to addiction, addiction vulnerability may also depend on the ease of transition from a
drug-naïve to a drug-dependent brain state. In order to assess the relative influence of each
brain region on the minimum energy associated with each transition, we calculated the change in
minimum control energy following suppression of each brain region in the network (24). This
simulated suppression of activity may be conceptualized as inhibitory neuromodulation, such as
that induced by optogenetic inhibition (33), or noninvasively by transcranial magnetic stimulation
(TMS) (19, 34, 35). Clinically, such inhibitory neuromodulation could arise from aberrant brain
pathology that involves region damage or loss.

In the naïve state, morphine increased FOS expression in eight regions of interest: the dACC,
vACC, Cla, CPu, NAc, BNST, BLA, and VTA. These regions represent components of the
mesocortical and mesolimbic dopamine systems which are implicated in drug incentive salience
and acute reinforcing effects, respectively (36). In particular, dopaminergic neurons that project
from the VTA to the NAc and cortical regions play an important role in acute, rewarding effects of
morphine and other drugs of abuse (37-39). Several of these regions (the vACC, CPu, NAc and
BNST) were among those found to significantly influence minimum control energy for the
transition from the naïve state to the 24 h “dependent” state. Of interest, regions that showed
significant differences in FOS expression between the naïve and 24 h states (the dACC and BLA)
were not among those found to significantly influence control energy for the state transition.

The dorsal striatum (CPu), dentate gyrus (DG), and periaqueductal grey (PAG) regions were
found to most strongly influence the minimum control energy required to transition from an opiatenaïve to an opiate-dependent state (Naïve to 24 h). The observed state transitions occur as a
result of external inputs that include opiate exposure, and thus, in theory, more of that input would
be required if a particularly influential region was suppressed. This suggests that inhibiting a
region that strongly influences minimum control energy would prevent opiate exposure from
leading to the dependent activity state.
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Among the regions included in our analysis, the CPu also had the highest weighted degree in the
24 h state. This finding is consistent with previous work demonstrating that weighted degree is
highly correlated with average controllability; specifically, suppression of regions with stronger
connectivity increases minimum control energy more than suppression of regions with weaker
connections (19). The CPu or dorsal striatum, in addition to having a role in motor function, is
involved in a number of important functions including cognition, decision-making, motivation, and
reward perception (40-42). The location of the CPu in the structural network suggests that it also
has an important role in the transition of the brain from a naïve state to an opioid-dependent
state, and by extension, the behaviors associated with brain activity patterns in those states as
well.

The dentate gyrus region of the hippocampus is critical for the acquisition of new memories and
as such, plays a critical role in the storage of information relevant to drug cues and environmental
stimuli associated with drug taking behavior. Many addictive drugs, particularly after chronic
administration, have been shown to promote synaptic plasticity in this region (43, 44). Further, our
gene coexpression analysis identified Synaptic Long Term Potentiation and Synaptogenesis
Signaling as two of the top pathways associated with stronger transcriptional coupling between
regions with increased connectivity following opioid dependence. Thus, it is not surprising that the
DG was identified as a prominent brain region influencing the transitions in brain state following
opiate exposure.

The PAG is primarily associated with analgesia and tolerance to opioids. Opioid-sensitive
neurons in the PAG have been shown to be hyperexcited during opioid withdrawal (45) and the
PAG receives input from both cortical and midbrain regions. Thus, the PAG is well positioned for
coordinating functional transitions between brain states associated with dependence and
withdrawal. While these three brain regions were not the only ones identified that influence
control energy for state transitions following opioid exposure and withdrawal, they are functionally
plausible as control regions to help mediate transitions in brain state following opiate exposure.
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Methodological Considerations. We note several methodological considerations pertinent to this
work. First, the brain regions included in this analysis were chosen based on their known
involvement in opiate reward, dependence, and withdrawal, and were intended to be
representative. To more completely characterize whole brain connectivity under various drug
states, future studies could include additional brain regions to promote a better understanding of
how opioid dependence may alter associations between brain regions that are directly implicated
in drug dependence and those that are not. Second, the network control approach that we used
here assumes that activity flows along structural paths alone and follows linear dynamics (46). An
extension to nonlinear dynamics constitutes a natural direction for future work.

Conclusion.
Here, we report findings from a network analysis of FOS expression in 19 brain regions following
acute morphine exposure in animals that were drug-naïve, drug-dependent, or had undergone 4
weeks of withdrawal from chronic morphine exposure. We have combined the descriptive power
of graph theory with the explanatory power of network control theory to identify opiate-induced
alterations to FOS correlation networks. This innovative approach allows us to understand not
only what changes occur but how they occur in the context of opioid dependence. Approaches
like this can eventually provide a theoretical foundation upon which to understand the effects of
interventions on the brain at a systems level.

Methods
Animals
Eight-week-old male C57BL/6 mice (n = 34 mice total; 8-9 per treatment group) obtained from
Taconic Biosciences were used in the experiments. Mice were maintained on a standard light
cycle (lights on between 0600 and 1800 h), with ad libitum access to food and water. All
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experimental procedures were approved by the University of Pennsylvania’s Animal Care and
Use Committee.

Drug Exposure
Morphine sulfate was obtained from the NIDA Drug Supply (Research Triangle Park, NC), and
dissolved in 0.9% saline. Dependence was induced by repeated, subcutaneous (s.c.) injections of
escalating doses of morphine (Fig. 2.1; SI Appendix, Fig. S2.1). Prior to tissue collection, an
acute dose of 10 mg/kg s.c. morphine was given to induce FOS expression in each group of
mice.

FOS Immunohistochemistry
Mice were deeply anesthetized with sodium pentobarbital (50mg/kg i.p.) 90 min after receiving an
injection of 10 mg/kg morphine (s.c.) and were perfused with 20-30 ml ice-cold 0.01M phosphatebuffered saline (PBS), followed by 40-50 ml ice-cold 4% paraformaldehyde (PFA). Brains were
post-fixed overnight in 4% PFA and cryoprotected in 30% sucrose at 4°C. Brains were then
frozen at -20°C and 30 micron sections were cut on a cryostat.

After slide mounting, sections were washed 4×10 min in 0.01M PBS, blocked for 1 h in 0.01M
PBS containing 5% normal goat serum and 0.3% Triton X-100, and incubated overnight at room
temperature in rabbit anti-cFOS primary antibody (Cell Signaling 2250S; 1:300 dilution). Sections
were then washed 4×10 min in 0.01M PBS, incubated for 1 h in goat anti-rabbit Alexa Fluor 488
secondary antibody (1:1000 dilution), and again washed 4×10 min in 0.01M PBS. Prior to
imaging, slides were coverslipped with DAPI Fluoromount.

Image Acquisition and Quantification
The following regions were imaged and included in the analysis: dorsal and ventral anterior
cingulate cortex (dACC and vACC), dorsal and ventral agranular insula (AId and AIv), claustrum
(Cla), caudate putamen (CPu), nucleus accumbens (NAc), ventral pallidum (VP), bed nucleus of
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the stria terminalis (BNST), basolateral amygdala (BLA), central amygdala (CeA), dentate gyrus
(DG), medial and lateral habenula (MHb and LHb), paraventricular nucleus of the thalamus
(PVT), periaqueductal gray (PAG), compact and reticular regions of the substantia nigra (SNc
and SNr), and ventral tegmental area (VTA). Images were acquired as 1-µm z-stacks at 20x
magnification on a Keyence BZ-X800 fluorescence microscope and stitched to capture entire
brain regions within the coronal plane. The maximum projection images were used to quantify
FOS expression. Regions of interest were defined according to the Allen Mouse Brain Atlas (27),
and FOS-expressing cells within each region were quantified using Fiji software (47). FOSpositive cells per mm2 were counted and summed across both hemispheres by two
experimenters blinded to treatment condition and averaged across 3 sections per brain region. In
order to account for FOS expression induced by handling and injection stress, quantifications of
FOS expression for each mouse were normalized to the mean FOS expression of saline-injected
controls to compute fold change (Fig. 2). Two-way ANOVA of fold change in FOS expression was
performed using GraphPad Prism software, and p values were Bonferroni-corrected for multiple
comparisons.

Network Construction
Undirected, weighted networks were constructed in which brain regions of interest served as
nodes, and positive pairwise Pearson’s correlations in fold change in FOS expression across
animals served as edges between nodes (48). A one-way ANOVA was used to compare Fisher ztransformed correlation coefficients between states. Correlation matrices were generated using
the package 'corrplot' (49), represented as graphs, and both visualized and analyzed using the
package 'igraph' (50) within R (51). The two-dimensional projections of networks for visualization
purposes were constructed using the Fruchterman-Reingold algorithm (52).

In the context of our work, regions of the network are deemed to be “connected” when there exist
statistical dependencies in interregional patterns of neuronal activity across animals. Thus,
differences in interregional correlation values between states reflect increases or decreases in the
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similarity of interregional neuronal activity patterns induced by chronic opiate exposure. Regions
that display positive interregional correlations in neuronal activity are understood to be
functionally associated, and changes in correlation values may reflect altered communication
between brain regions.

Local Characteristics of Network Connectivity
To characterize FOS correlation network connectivity, we computed the distributions of weighted
degree and weighted betweenness centrality for each network. Weighted degree gives the
number of edges connected to a node, weighted according to strength; in this case, the weight
reflected the strength of the positive pairwise correlation. The weighted degree is defined as
#
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number of weighted shortest paths between node ℎ and node 𝑗 that pass through node 𝑖 (53).
Weighted degree and weighted betweenness centrality were computed using the package
‘igraph’ within R, and two-sample Kolmogorov–Smirnov tests were used to compare the
distributions of degree and betweenness centrality between each pair of states. The resultant p
values were Bonferroni-corrected for multiple comparisons.

Gene Expression Analysis
Regional gene expression data were obtained from the Allen Mouse Brain Atlas microarray data
available

at

http://download.alleninstitute.org/informatics-archive/october-
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2014/mouse_expression/mouse_expression_data_sets.csv. For each available experiment, we
first normalized the expression intensity of each gene across regions using a sigmoid function (16)
in order to account for arbitrary differences in baseline signal across experiments. This process
yields an 𝑁 × 1 vector of gene expression on a scale of 0 to 1 for each experiment for each gene,
where 𝑁 is the number of brain regions (here, the 19 brain regions assayed for FOS expression).
Next, for each gene, we averaged expression vectors across all available probes and experiments,
yielding an 𝑁 × 19,616 matrix of gene expression values for each region.

We assessed gene coexpression patterns by calculating pairwise interregional Pearson’s
correlations in expression across 19,616 genes. We adjusted for spatial correlations in the data by
fitting an exponential decay curve 𝑟+ (𝑑!" ) = 1.2201e(-0.6008 𝑑!" ) – 0.1491 (SI Appendix, Fig. S4).
To understand the relationship between gene coexpression and opiate-induced change in
connectivity strength, we performed a linear regression of mean gene coexpression with change in
weighted degree from the opiate-naïve to opiate-dependent state for each brain region. We then
used a two-sided Welch’s t-test to compare gene coexpression between all pairs of brain regions
that show increased connectivity strength and all pairs of brain regions that show decreased
connectivity strength following opiate dependence. In order to identify the specific genes that
contribute to higher gene coexpression between brain region pairs that show increased FOS
correlation networks after opioid dependence, we computed a gene coexpression contribution
(GCC) score for each gene, which is defined as
(-)

(-) (-)

𝐺𝐶𝐶!" = 𝑔<! 𝑔<"
(-) (-)

where 𝑔<! 𝑔<"

− 𝑟+ (𝑑!" ) ,

is the product of z-scored, normalized gene expression values for gene 𝑎 in brain

regions 𝑖 and 𝑗 (16).

One-sided Welch’s t-tests were used to identify genes that significantly contribute to the observed
higher gene coexpression levels amongst increased functional associations compared to
decreased functional associations. To relate significantly-associated genes to functional pathways,
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we then performed gene function analysis using Ingenuity® Pathway Analysis (Version 01-14;
QIAGEN, Redwood City). IPA uses a Fisher’s Exact Test to identify canonical pathways that are
significantly associated with the genes of interest relative to the entire IPA knowledge base.

Network Control
To understand how the brain is driven from an opiate-naïve to an opiate-dependent state, taking
into consideration the structural connectivity of its component regions, we used a network control
theory approach. Network control theory explains how to manipulate the state of a system of
interconnected units (12, 54, 55). Given an understanding of the connections between elements
in a system and the dynamics or activity of those elements, we can use network control theory to
make predictions about the behavior of the system (18).

The simplified mathematical model that we used to describe the brain’s dynamics when it is
driven along a particular trajectory by injecting control signal or input is defined as
𝑥̇ = 𝐴𝑥(𝑡) + 𝐵/ 𝑢/ (𝑡),
where 𝑥(𝑡) is an 𝑁 × 1 vector representing the state of the brain; in this case, each state is the
fold change in FOS expression across 𝑁 = 19 brain regions. The matrix 𝐴 is an 𝑁 × 𝑁 adjacency
matrix representing the relationships between brain regions; in the context of this work, it
represents the density of axonal projections between each pair of regions(27). When all brain
regions are controlled, 𝐵/ is an 𝑁 × 𝑁 identity matrix with ones along the diagonal and zeros
elsewhere. The variable 𝑢/ (𝑡) is an 𝑁 × 1 vector reflecting the amount of control input into each
of the 𝑁 control regions at each time point 𝑡.

We computed the minimum control energy to transition between opiate-naïve and opiatedependent brain states and used these values to determine the relative influence of each brain
region on the state transition. The minimum control energy is the minimum energy of a control
input to drive the brain from an initial state 𝑥(0) = 𝑥0 to a target state 𝑥(𝑇) = 𝑥1 over time horizon
𝑇. To compute minimum control energy, the activity level (FOS expression) for each brain region
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in each state is specified, as is the control set 𝐵/ . In order to compute the change in minimum
control energy induced by removing brain region 𝑖 from the control set, the 𝑖-th diagonal element
in 𝐵/ is replaced with a zero, and control energy in the full control condition is subtracted from the
resulting control energy. In our study, minimum control energy was computed with a time horizon
of 1 (26). Of note, we found that varying the time horizon did not alter the distribution of the
results (SI Appendix, Fig. S2.5).

Minimum control energy was computed using MATLAB software. Structural connectivity data for
regions corresponding to those included in the FOS correlation networks analysis were obtained
from the Allen Mouse Brain Connectivity Atlas (27). Structural connectivity data were obtained
from adult male C57BL/6 mice and represent the density of axonal projections mapped from each
tracer-injected source node to its ipsilateral target node. Functional data under each state were
represented by fold change in FOS expression for each brain region.

In order to statistically compare the relative influence of each brain region in the network on the
minimum control energy necessary for each state transition, we computed the minimum control
energy between every possible pair of FOS expression vectors in each state (e.g., given n=8
mice in the Naïve group and n=9 mice in the 24 h group, 72 vector pairs are possible) after
suppression of each brain region, as described above. One-sided Welch’s t-tests were used to
identify brain regions that significantly influence the minimum control energy for each state
transition relative to other brain regions. All p-values were Bonferroni-corrected for multiple
comparisons and were combined using Fisher’s method to obtain a single p-value for each
region.

Data Availability
FOS expression data and all code used for the analyses are available
at https://github.com/jkbrynildsen/opiateFOSconnectivity. Structural connectivity data and
interregional distance data are available from the Allen Institute (27). Regional gene expression
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microarray data from the Allen Mouse Brain Atlas are available
at http://download.alleninstitute.org/informatics-archive/october2014/mouse_expression/mouse_expression_data_sets.csv.
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Tables
Table 2.1. Genes implicated in synaptic plasticity are associated with changes to FOS
correlation networks following opioid dependence.
Pathway

Ratio

P value

Fcγ Receptor-mediated Phagocytosis in Macrophages and
Monocytes

0.266

1.15E-06

Neuropathic Pain Signaling In Dorsal Horn Neurons

0.257

1.38E-06

Endocannabinoid Neuronal Synapse Pathway

0.242

6.03E-07

Synaptic Long Term Potentiation

0.240

7.24E-07

Reelin Signaling in Neurons

0.233

2.24E-06

CREB Signaling in Neurons

0.203

1.23E-06

Integrin Signaling

0.197

2.69E-06

Synaptogenesis Signaling Pathway

0.192

5.62E-08

Molecular Mechanisms of Cancer

0.187

7.76E-09

Pathways most highly significantly-associated with increased gene coexpression among pairs of
brain regions showing increased connectivity following opioid dependence compared to pairs of
brain regions showing decreased connectivity. Pathways are ranked in order of the proportion of
overlap between significantly-associated genes and total genes within the pathway (Ratio).
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Table 2.2. Relative influence of individual brain regions on minimum control energy for
opiate-induced state transitions.
P value
Region

Naïve to 24 h

24 h to 4 week

dACC

1

0.9817

vACC

1.29E-09

1.51E-15

AId

1

0.9902

AIv

0.9191

0.9817

Cla

1

1

CPu

2.31E-42

6.99E-32

NAc

1.45E-18

2.02E-15

VP

3.06E-25

2.02E-15

BNST

1.82E-28

1.46E-22

BLA

1

0.9902

CeA

1.32E-28

6.99E-32

DG

2.31E-42

6.99E-32

MHb

1

1

LHb

0.9999

2.02E-15

PVT

1

1

PAG

1.75E-35

2.47E-46

SNc

1

1

SNr

1.82E-28

7.79E-39

VTA

1

2.02E-15

P-values associated with the relative influence of each brain region on the minimum control
energy for the transition from the naïve to 24 h state, and from the 24 h to 4 week state, as
inferred from the increase in minimum control energy induced by removal of each region from the
control set. A single p-value for each region was obtained by using Fisher’s method to combine pvalues from one-sided Welch’s t-tests between each region and all other regions in the network.
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Figures

Figure 2.1. Experimental schematic. a, Three groups of mice were administered 10 mg/kg
morphine in three states: drug-naïve, 24 h after chronic morphine, and 4 weeks after chronic
morphine. The chronic morphine exposure paradigm consisted of 5 days of repeated
subcutaneous injections of escalating doses of morphine. Doses shown are in mg/kg. Control
animals were given injections of saline instead of morphine. b, Tissue was collected 90 min after
the last injection, 30 µm sections were cut on a cryostat, and populations of neurons were
quantified within 19 brain regions of interest. c, Interregional correlation matrices were generated
from Fos quantification data. d, FOS correlation networks were used to formally represent
interregional correlation matrices.
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Figure 2.2. Acute morphine increases Fos expression in a state-dependent manner.
Fold change in FOS expression relative to saline group in 19 brain regions. Male C57BL/6 mice
(n=8-9 per group) were administered an injection of 10 mg/kg morphine after no prior drug
exposure (Naïve), 24 hours after chronic exposure (24 h), or 4 weeks after chronic exposure (4
weeks), and tissue was collected 90 min later. The influence of treatment on fold change in FOS
expression across brain regions was analyzed by two-way ANOVA. Bonferroni-corrected
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Error bars represent SEM.
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Figure 2.3. Opioid dependence alters local features of FOS correlation network
connectivity. a, Interregional correlation matrices reflecting pairwise correlations in FOS
expression between 19 brain regions of interest. b, Distribution of Fisher’s z-transformed positive
Pearson’s r values across states. c, Graph representations of FOS correlation networks reflecting
the correlation matrices. Nodes represent brain regions, and edges represent positive pairwise
correlations in FOS expression, weighted according to the strength of the correlation. Nodes are
colored to reflect their anatomical class. d, Weighted degree in each state. e, Illustration of
degree. Each of the gray nodes has a degree of 1, while the white node has a degree of 2. f,
Betweenness centrality in each state g, Illustration of betweenness centrality. The red node falls
on the shortest paths (highlighted) between each of the gray nodes and the white node.
Distributions of weighted degree and betweenness centrality were compared via two-sided
Kolmogorov-Smirnov test. Bonferroni-corrected *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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Figure 2.4. Gene coexpression patterns predict changes in network connectivity strength
induced by opiate dependence. a, Linear regression between gene coexpression and the
change in FOS correlation networks from an opiate-naïve state to 24 h after withdrawal from
chronic exposure. b, Distribution of edges showing increased weight following opiate
dependence, compared to edges showing decreased weight following opiate dependence.
**p<0.01.
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Figure 2.5. Region-specific effects on control energy to drive the brain from a drug-naïve
to a drug-dependent state. a, Structural connectivity matrix representing quantitative projection
strength values from the Allen Mouse Brain Connectivity Atlas. b, Increase in minimum control
energy to drive the brain between states. Brain images represent FOS expression levels in each
state, where colors represent anatomical groups, and opacity represents the expression level
(more opaque indicates higher expression). Bar graphs depict the mean increase in minimum
control energy following suppression of each region in the transition from the naïve to the 24 h
state, and from the 24 h to the 4 week state. Error bars represent SEM.

53

Supplementary Information

Figure S2.1. Naloxone-precipitated somatic signs of opiate withdrawal following chronic
morphine exposure. We used a twice-daily, escalating dosing paradigm to induce morphine
dependence before collecting tissue at the 24 h and 4 week time points (Fig. 2.1). In order to
confirm that our chronic morphine exposure paradigm was sufficient to induce dependence, we
administered an injection of 1 mg/kg naloxone (s.c.) and quantified somatic signs of withdrawal in
a separate group of male C57BL/6 mice that had received chronic morphine (n=7) or saline (n=6).
Occurrences of the following somatic signs were scored for 30 min and summed: genital licking,
gnawing, head shakes, body shakes, paw tremors, scratches, backing, and jumps. Additionally,
the presence of the following signs was recorded in 1-min bins for the 30 min duration: ptosis,
resting tremor, diarrhea, and teeth chatter. Mice were tested at 24 h and 1 week after chronic
exposure. Analysis of somatic signs by two-way repeated measures ANOVA revealed a
significant time × treatment interaction (F1,11 = 30.87; p = 0.0002), whereby only morphine-treated
mice displayed significantly elevated somatic signs of withdrawal at 24 h (Bonferroni-corrected p
< 0.0001). Precipitated signs of withdrawal in the morphine-treated group were no longer evident
after 1 week. ****p < 0.0001. Error bars represent SEM.
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Figure S2.2. Opiate-induced changes in FOS correlation networks are robust to differences
in correlation type. Plots are the same as in Fig. 2.3 but are based on Spearman correlations
rather than Pearson correlations. a, Interregional correlation matrices reflecting pairwise
correlations in FOS expression between 19 brain regions of interest. b, Distribution of Fisher’s ztransformed positive Spearman’s correlation values across states. c, Graph representations of
connectivity networks reflecting the correlation matrices. Nodes represent brain regions, and
edges represent positive pairwise correlations in FOS expression, weighted according to the
strength of the correlation. Nodes are colored to reflect their anatomical class. d, Weighted
degree in each state. e, Betweenness centrality in each state. Distributions of weighted degree
and betweenness centrality were compared via two-sided Kolmogorov-Smirnov test. Bonferronicorrected *p<0.05, ****p<0.0001.
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Figure S2.3. Comparison of graph theory metrics by region. Mean weighted degree (a) and
mean weighted betweenness centrality (b) in six groups of brain regions across each treatment
condition (Naïve, 24 h, and 4 weeks after chronic morphine) were analyzed by two-way ANOVA.
Brain region groups include the cortex (dACC, vACC, AId, AIv, and Cla), striatum (CPu and NAc),
pallidum (VP and BNST), amygdala (BLA and CeA), hippocampus/thalamus (DG, MHb, LHb, and
PVT), and midbrain (PAG, SNc, SNr, and VTA). ****p<0.0001. Error bars represent SEM.
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Figure S2.4. Spatially corrected gene coexpression. a, Using Cartesian distance data from the
Allen Institute, we identified an inverse relationship between gene coexpression and spatial
distance between brain regions, which is fitted by the exponential decay equation shown. b, After
correcting for the exponential distance relationship shown in a, no relationship between gene
coexpression and distance is evident. The significant linear relationship between change in
weighted degree and gene coexpression shown in panel a is maintained after spatial correction.
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Figure S2.5. No effect of varying time horizon on the distribution of minimum control
energy values. We repeated the analysis shown in Fig. 5.5 using the mean FOS expression
vector for each group (Naïve, 24 h, and 4 weeks) with time horizons of T=0.5, T=1, T=5, and
T=10. We used a two-sample Kolmogorov-Smirnov test to compare the distributions of change in
minimum control energy induced by suppressing each brain region and identified no significant
differences between any pair of distributions (D ≥ 0.0526, p ≥ 0.5262), suggesting that the results
shown in Fig. 5 are not dependent on the time horizon parameter.
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Abstract
The single nucleotide polymorphism (SNP) D398N (rs16969968) in CHRNA5, the gene encoding
the α5 subunit of the nicotinic acetylcholine receptors (nAChR), has been associated with both
nicotine and opiate dependence in human populations. Expression of this SNP on presynaptic
VTA dopaminergic (DA) neurons is shown to cause a reduction in calcium signaling, leading to
alterations in transmitter signaling and altered responses to drugs of abuse. To examine the
impact of the Chrna5 SNP on opiate reward and underlying DA signaling mechanisms, mice
harboring two copies of the risk-associated allele (Chrna5 A/A) at a location equivalent to human
rs16969968 were generated via CRISPR/cas9 genome editing. We sought to determine whether
Chrna5 A/A mice show differences in sensitivity to rewarding properties of morphine using the
conditioned place preference paradigm. When mice were tested two weeks after conditioning,
female Chrna5 A/A mice showed significantly enhanced preference for the morphine-paired
chamber (p = 0.0235) relative to WT females, suggesting that this genotype may enhance opioid
reward specifically in females. In contrast, Chrna5 genotype had no effect on locomotor
sensitization in male or female mice. Relative to WT females, peak current amplitude recorded
from VTA DA neurons in Chrna5 A/A females was potentiated 1 day after conditioning with
morphine. Increased FOS expression was also observed in the VTA-NAc circuit of Chrna5 A/A
mice. We propose that impaired a5 nAChR subunit function enhances DA neuron response
following repeated morphine exposures, which contributes to enhanced opiate reward two weeks
after conditioning.
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Introduction
Drug abuse phenotypes are known to have a strong heritable component; genetics account for as
much as 60% of the risk for nicotine and alcohol dependence and as much as 80% of the risk for
cocaine and opioid dependence (1, 2). As such, understanding how genetic factors contribute to
drug abuse liability is an important aim. Human genome-wide association studies (GWAS) have
identified common single nucleotide polymorphisms (SNPs) in a number of genes that are
relevant to drug addiction. Among these, a SNP in the gene CHRNA5, which encodes the a5
nicotinic acetylcholine receptor (nAChR) subunit, has been repeatedly associated with
dependence to nicotine (3-6), and to opioids (7, 8).

In vitro studies have demonstrated that the Chrna5 SNP affects the function of a5-containing
nAChRs by inhibiting calcium ion trafficking through the receptor (5, 9-11). Receptors containing
the a5 subunit are expressed on dopaminergic (DA) cell bodies within the VTA and on DA
terminals in the striatum (12, 13); therefore, the presence of the SNP could inhibit the ability of the
cholinergic system to modulate dopamine release within these reward-encoding regions. Also
expressed within the midbrain DA system are mu opioid receptors (MORs), which are implicated
in the rewarding effects of morphine and other opioids. Opiate drugs bind to MORs in the ventral
tegmental area (VTA) thereby inhibiting the activity of GABAergic interneurons and indirectly
stimulating dopamine release in the nucleus accumbens (NAc) (14). Considering the overlapping
expression of MORs and a5-containing nAChRs within the midbrain dopaminergic circuitry, it
follows that a5 nAChRs could impact opiate reward.

Based on the evidence for opioid and cholinergic system interactions, and the association of the
CHRNA5 genetic variant with opioid dependence, we hypothesized that the Chrna5 SNP
influences morphine reward by impacting the function of DA signaling within the VTA. In this
study, we provide evidence that the Chrna5 SNP enhances opiate reward in female mice and
identify a cellular correlate that may underlie this phenotype.
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Results
Chrna5 A/A genotype enhances morphine reward in female mice two weeks after conditioning
To assess the hypothesis that Chrna5 genotype alters morphine reward, we tested mice in the
conditioned place preference (CPP) paradigm. Mice were conditioned with once-daily alternating
injections of saline and morphine (10 mg/kg, s.c.) over a period of 8 days. Preference was
assessed one day prior to morphine conditioning (pretest), one day after conditioning and two
weeks after conditioning.

Analysis of CPP data from female mice by two-way repeated measures ANOVA revealed a
significant main effect of time (F[2,40] = 29.40, p < 0.0001) and significant time × genotype
interaction (F[2,40] = 3.311, p = 0.0467). Both WT and Chrna5 A/A females showed a significant
preference for the morphine-paired chamber one day and two weeks after the final conditioning
session relative to pretest (p < 0.0100), and Chrna5 A/A females additionally showed a
significantly greater preference for the morphine-paired chamber at two weeks relative to one day
after conditioning (p = 0.0443). Further, relative to WT females, Chrna5 A/A females showed a
significantly enhanced preference for the morphine-paired chamber two weeks after conditioning
(p = 0.0235) (Fig. 3.1).

Analysis of CPP data from male mice by two-way repeated measures ANOVA also revealed a
significant main effect of time (F[2,38] = 30.53, p < 0.0001) but no effect of genotype and no time ×
genotype interaction. Relative to pretest, male mice of both genotypes showed a significant
preference for the morphine-paired chamber one day (p < 0.0100) and two weeks (p < 0.0001)
after the last conditioning session (Fig. 3.1).

Chrna5 genotype does not impact morphine-induced locomotor sensitization
Locomotor sensitization is thought to be related to drug reward because of the shared neural
correlates within the midbrain-striatal DA system (15). To determine whether the Chrna5 SNP
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alters morphine-induced locomotor sensitization, we recorded locomotor activity during each CPP
conditioning session.

We define sensitization as a significant increase in locomotor activity following repeated
administration of morphine. Both Chrna5 G/G and Chrna5 A/A male mice showed sensitization to
repeated morphine exposures, as evidenced by a significant main effect of time (F3,57 = 65.41, p <
0.0001), whereby locomotor activity was significantly increased on the second, third and fourth
morphine conditioning days relative to the first (p < 0.0001) (Fig. 3.2). Significant sensitization
was also observed in female mice of both genotypes (F3,63 = 20.24, p < 0.0001), whereby
locomotor activity was significantly increased on the third and fourth conditioning day relative to
the first (p < 0.0100). There was no effect of genotype and no time × genotype interaction for
either sex.

Chrna5 genotype moderates the effect of repeated morphine exposure on nAChR function of DA
neurons in the VTA of female mice
The Chrna5 SNP compromises the function of a5-containing nAChRs, which are expressed on
DA cell bodies within the VTA and on DA terminals in the NAc (12, 13). We hypothesized that the
Chrna5 SNP impacts opiate reward in female mice via its effect on DA signaling from the VTA.
VTA DA cells were recorded ex vivo from 3-6 animals per group after each CPP test, and peak
current amplitudes for each cell were pooled prior to analysis. Analysis by two-way ANOVA
revealed a trending effect of genotype on peak current amplitude (F1,42 = 3.836, p = 0.0568) (Fig.
3.3). There was no effect of treatment group and no time × genotype interaction. Via Bonferroni
post-hoc tests, we found that peak current amplitude was significantly greater in Chrna5 A/A
females compared to WT females one day after morphine conditioning (p = 0.0199).

Chrna5 genotype potentiates FOS expression after morphine conditioning in female mice
We hypothesized that greater neuronal activation in VTA projection regions, particularly the NAc,
which is implicated in drug reward, would be observed following potentiated whole cell currents
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one day after morphine conditioning in female mice. To test this hypothesis, FOS expression was
quantified in the VTA and NAc after the CPP test one day and two weeks post-conditioning. Data
were analyzed by three-way ANOVA, which identified a significant main effect of genotype (F1,34 =
4.738, p = 0.0365) and near-significant main effect of time (F1,34 = 3.908, p = 0.0562). FOS
expression levels were higher in Chrna5 A/A mice compared to WT mice, and a trend toward
higher FOS expression was observed at two weeks relative to one day post-conditioning (Fig.
3.4).

Methods
Animals
Mice with two copies of the minor ‘A’ allele at Chrna5 were generated using CRISPR/cas9assisted genome editing. A mixture of single-stranded guide RNAs, donor template DNA, and
mRNA encoding the cas9 nickase was injected into fertilized C57BL/6 oocytes. After incubation in
the NEHJ inhibitor SCR7, zygotes were implanted into the uterus of pseudo-pregnant females.
Pups were genotyped using PCR amplification of the targeted region followed by Taq1 digest.

Male and female Chrna5 G/G (WT) and Chrna5 A/A mice (8 to 16 weeks of age) were used in the
experiments. Mice were maintained on a standard light cycle (lights on between 0600 and 1800
h) with ad libitum access to food and water and were housed in groups of 2-4. All experimental
procedures were approved by the University of Pennsylvania’s Animal Care and Use Committee.

Conditioned Place Preference
Mice were tested and conditioned in MED Associates automated CPP chambers. The chambers
consist of two compartments, each with distinct tactile and visual cues, which are separated by a
guillotine door. One compartment has black walls with white stripes and a mesh floor; the other
compartment has white walls with black circles and a barred floor. The guillotine door is left open
during testing sessions to allow mice to explore both sides of the apparatus, and closed during
conditioning sessions, such that the mice are confined to one side or the other.
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After initial preference was measured (pretest), mice underwent a total of 4 saline and 4 morphine
(10 mg/kg s.c.) conditioning sessions, which took place once per day. Conditioning was
performed using an unbiased, counterbalanced design. Animals that spent more than 700
seconds in either side of the apparatus during the pretest were excluded from the remainder of
the study. On conditioning days, mice were injected with morphine or saline and immediately
confined to one side of the apparatus. Preference was then measured one day (Test 1) and two
weeks (Test 2) after the last conditioning session. Pretest and Test sessions were 15 minutes in
duration, and conditioning sessions were 30 minutes in duration. At each test, a “preference
score” was obtained by subtracting time spent in the saline-paired chamber from time spent in the
morphine-paired chamber.

Locomotor Activity
To assess locomotor activity, beam breaks were recorded using MED Associates software during
each 30-min CPP conditioning session. Activity counts were summed within each conditioning
session and compared across sessions.

Ex vivo Slice Electrophysiology
Ex vivo slice electrophysiology experiments were performed approximately 1 hour after CPP
testing, and 24 hours or two weeks after the final morphine conditioning session. Mice were
anesthetized with a combination of ketamine and xylazine, and brains were removed and
sectioned on a vibratome. VTA-containing sections were maintained in artificial cerebrospinal
fluid (ACSF) (in mM): 125 NaCl, 25 NaHCO3, 2.5 KCl, 1.25 NaH2PO4, 1 MgSO4, 2 CaCl2, 25 D(+)-glucose at 32-34°C. Acetylcholine (Ach) 1 mM was puff-applied under voltage-clamp
conditions, and ACh-gated whole-cell currents were recorded in VTA DA neurons of Chrna5 G/G
and Chrna5 A/A mice.

Immunohistochemistry
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FOS expression in the VTA and NAc was measured 1 day and 2 weeks after conditioning with
morphine or saline. Mice underwent a 15 min CPP test, as described above, and 90 min later
were anesthetized with sodium pentobarbital (50 mg/kg, i.p.) and transcardially perfused with 2030 ml ice-cold PBS, followed by 50-60 ml ice-cold 4% paraformaldehyde (PFA). Brains were
extracted, post-fixed overnight in 4% PFA, and cryoprotected in 30% sucrose solution prior to
sectioning on a cryostat.

Brains were rapidly frozen at -80°C and 30-micron sections were cut on a cryostat at 20°C. Slidemounted tissue sections were then washed four times for 10 min in 0.01M PBS, blocked for 1
hour in 0.01M PBS containing 5% normal goat serum and 0.3% Triton X-100, and incubated
overnight at room temperature in rabbit anti-cFOS primary antibody (1:300 dilution, 2250S; Cell
Signaling). Sections were then washed four times for 10 min in 0.01M PBS, incubated for 1 hour
in goat anti-rabbit Alexa Fluor 488 secondary antibody (1:1,000 dilution), and again washed four
times for 10 min in 0.01M PBS. Prior to imaging, slides were coverslipped with DAPI
Fluoromount.

Images of the NAc and VTA were acquired on a Keyence BZ-X810 fluorescence microscope and
processed as previously described (16). FOS-expressing cells were quantified by an
experimenter blinded to treatment condition using Fiji software, summed across both
hemispheres and averaged across three sections per brain region (16).

Statistics
CPP data were analyzed by two-way repeated measures ANOVA, with genotype (Chrna5 G/G
and Chrna5 A/A) and time (pretest, 1 day post, and 2 weeks post) as factors. Locomotor data
were similarly analyzed by two-way repeated measures ANOVA, with genotype (Chrna5 G/G and
Chrna5 A/A) and time (morphine conditioning day 1, 2, 3, and 4) as factors. Electrophysiology
data were analyzed by two-way ANOVA, with genotype (Chrna5 G/G and Chrna5 A/A) and
treatment group (naïve, 1 day post, and 2 weeks post) as factors. FOS expression data from
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morphine-treated mice were normalized to genotype- and time point-matched, saline-treated
controls to compute fold change. Fold change in FOS expression data were then analyzed by
three-way ANOVA, with genotype (Chrna5 G/G and Chrna5 A/A), time (1 day post and 2 weeks
post) and brain region (NAc and VTA) as factors. Data from males and females were analyzed
separately. Post hoc tests were Bonferroni-corrected for multiple comparisons. A p < 0.05 was
considered significant throughout.

Discussion
In this study, we demonstrate that Chrna5 A/A genotype potentiates morphine reward two weeks
after conditioning in female mice. We also determine that this genotype-specific behavioral effect
is preceded by enhanced peak current amplitude recorded from VTA DA neurons in Chrna5 A/A
mice relative to WT (G/G) mice and coincides with greater FOS expression.

A growing body of literature suggests that the Chrna5 SNP moderates sensitivity to the rewarding
properties of both drugs and natural reward and to relapse liability (17). Rats expressing the
Chrna5 SNP self-administer more nicotine at higher doses, and show increased nicotine-induced
reinstatement to nicotine-seeking (18). They also show greater relapse liability to both alcohol
and food in a self-administration paradigm (19). Nonsignificant increases in FOS expression have
been observed in regions of the NAc core and shell in Chrna5 SNP rats relative to WT rats in an
alcohol relapse model (19). Taken together with our current results, these findings support the
notion that Chrna5 D398N may influence drug reward via its impact on DA signaling.

The increased place preference observed in female mice two weeks after conditioning could be
indicative of enhanced drug craving, which represents a risk factor for relapse. Conditioned place
preference has previously been used to model incubation of opiate craving, a phenomenon
characterized by increases in drug-seeking behavior over the course of protracted abstinence
(20). Significant increases in preference score have been observed at one week and two weeks
after conditioning in the CPP paradigm (21). Other studies have shown that morphine-induced
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preference scores are maintained, but do not increase, across time (22, 23). In our study, we
observe that preference scores are maintained in WT mice of both sexes, and time-dependent
increases are observed only in female mice of the Chrna5 A/A genotype.

Increased morphine preference in female Chrna5 A/A mice may result from altered midbrain DA
signaling. Reinforcing effects of morphine are thought to be mediated by MORs expressed on
GABA neurons within the VTA and rostromedial tegmental nucleus (RMTg). These neurons
synapse onto DA neurons within the VTA, which in turn project to the NAc, amygdala and
prefrontal cortex; MORs stimulate DA release within these regions via disinhibition of DA
neurons. Opiate agonists may also act directly on MORs expressed in the NAc (24). a5containing nAChRs are expressed on DA neurons in the VTA and on DA neuron terminals in the
NAc (25, 26).

We speculate that enhanced peak current amplitude in VTA DA neurons of Chrna5 A/A females
one day after morphine conditioning may lead to increased opiate reward two weeks later.
Adaptations in the VTA during early incubation of cocaine craving appear to lead to changes in its
projection regions weeks later (27). Though the mechanism underlying this phenomenon is
currently unknown, given the role of VTA DA signaling in opiate reward, it is conceivable that
enhanced peak current amplitude could lead to incubation of opiate craving and greater FOS
expression in the NAc two weeks later. Further investigation will be necessary to elucidate the
contributions of specific cell types and transmitter systems within VTA-NAc circuitry to the
observed effects on opiate reward. Future studies will also examine neuronal activity within VTA
projection regions of the medial prefrontal cortex, which also express a5-containing nAChRs and
are implicated in drug reward and craving.

A limitation of this work is that we did not track the estrous cycle during the course of the
experiments, and thus cannot speak to the influence of hormonal fluctuations on the observed
phenotypes. a5 nAChR subunits are shown to sex-dependently impact anxiety-like behavior;
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unlike WT females, Chrna5 null mice do not show estrus-cycle dependent fluctuations in anxiety
(28). Differences in anxiety levels could impact behavior in the CPP paradigm (29). Further,
heroin intake has been shown to decrease during the proestrus phase of the rat estrous cycle
due to higher levels of circulating estradiol (30, 31). It is therefore conceivable that morphine
reward, as measured in the CPP paradigm, could also be influenced by the estrous cycle.

In conclusion, the present study provides evidence that Chrna5 D398N enhances opiate reward
in female mice via its influence on DA signaling. To date, only one other rodent study has
included both males and females (32). Further investigation of sex differences in the influence of
the Chrna5 SNP on substance abuse phenotypes is warranted, particularly given that human
studies suggest that this SNP affects smoking cue reactivity and responsivity to treatment
specifically in women (33, 34).
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Figures

Figure 3.1. Chrna5 A/A genotype enhances morphine reward in female mice. CPP
preference score (time spent in morphine-paired chamber minus time spent in saline-paired
chamber) in male (A) and female (B) mice (n=9-12/group). Preference scores were obtained one
day before conditioning (Pretest), and one day and two weeks after conditioning (1 Day Post and
2 Weeks Post). **p < 0.01, ***p < 0.001, ****p < 0.0001 relative to Pretest. #p < 0.05 relative to
WT. Error bars represent SEM.
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Figure 3.2. Chrna5 genotype does not impact morphine-induced locomotor sensitization.
Locomotor activity counts in male (A) and female (B) mice (n=9-12/group) on morphine
conditioning days. ****p < 0.0001 WT relative to Morphine Conditioning Session 1. ##p < 0.01,
###p < 0.001, ####p < 0.0001 Chrna5 A/A relative to Morphine Conditioning Session 1. Error
bars represent SEM.
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Figure 3.3. Peak current amplitude recorded from VTA DA neurons is higher in Chrna5 A/A
females compared to G/G females 1 day after morphine conditioning. Peak current
amplitude (pA) recorded from VTA dopamine neurons in mice (n=3-6/group) that were drugnaïve, 1 day post-conditioning with 10 mg/kg morphine, or 2 weeks post-conditioning with 10
mg/kg morphine. *p < 0.05. Error bars represent SEM.
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Figure 3.4. Augmented neuronal activation in Chrna5 A/A mice after morphine
conditioning. FOS expression was quantified in the VTA and NAc of morphine-conditioned mice
(n=5-6/group) and data from morphine-treated mice were normalized to genotype- and time pointmatched, saline-conditioned controls to compute fold change. *p < 0.05 main effect of genotype.
Error bars represent SEM.
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Abstract
Cigarette smoking is the leading cause of preventable disease and death in the United States, with
more persons dying from nicotine addiction than any other preventable cause of death. Even
though smoking cessation incurs multiple health benefits, the abstinence rate remains low with
current medications. Here we show that the AMPK pathway in the hippocampus is activated
following chronic nicotine, an effect that is rapidly reversed by nicotine withdrawal. Increasing
pAMPK levels and consequently downstream AMPK signaling pharmacologically attenuates
anxiety-like behavior following nicotine withdrawal. We show further that metformin, a known AMPK
activator in the periphery, reduces withdrawal symptoms through a mechanism dependent on the
presence of the AMPKα subunits within the hippocampus. These studies provide the first evidence
of a direct effect of AMPK modulation on nicotine withdrawal symptoms, and suggest central AMPK
activation as a novel therapeutic target for smoking cessation.

Key Words: Nicotine , Metformin, 5' AMP-activated protein kinase (AMPK), CREB
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Significance Statement
Cigarette smoking is the leading cause of preventable disease and death in the United States.
Severe withdrawal symptoms are the reason most people have a hard time quitting smoking.
AMP-activated protein kinase (AMPK) is a master regulator of energy homeostasis and is
activated in response to cellular stressors. We discovered that the AMPK pathway is activated
following chronic nicotine but is repressed following nicotine withdrawal. We reasoned that
increasing pAMPK levels pharmacologically might reduce symptoms of nicotine withdrawal. After
giving mice metformin, an AMPK activator, we were able to reduce nicotine withdrawal and found
that this was dependent on the presence of the AMPK protein in the hippocampus. These studies
suggest that AMPK activation could be a novel target for smoking cessation.
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Introduction
Cigarette smoking constitutes a major health burden in the US, with smoking accounting for over
500,000 deaths per year nationwide (1). Despite over 30 reports issued by the Surgeon General
and multiple public health campaigns addressing the negative impact of smoking on the health and
well-being of Americans, the cessation rate remains modest (1, 2). Multiple obstacles prevent a
successful quit attempt including irritability, anger, depressed mood, anxiety and difficulty
concentrating. There are three FDA-approved therapies used for targeting the symptoms of
withdrawal: nicotine replacement therapy, a nicotinic acetylcholine receptor (nAChR) partialagonist (Varenicline/Chantix®) and an anti-depressant (Bupropion/Zyban®) (3). However, although
70% of smokers express a desire to quit, current therapies achieve only a 15% success rate (1, 4).

Amongst cigarette smokers, nicotine has been shown to reduce anxiety. Given the lack of studies
on effects of nicotine in non-smokers, it is unclear whether nicotine reduces anxiety in the absence
of withdrawal. However, numerous studies in rodent models have demonstrated dose-dependent
anxiolytic effects of nicotine in drug-naïve subjects (5, 6). There is considerable evidence that
withdrawal-associated anxiety contributes to poor adherence to smoking cessation treatments (7,
8) as well as relapse rates, with many smokers experiencing anxiety symptoms during acute
abstinence periods (7, 9). A recent functional imaging study in smokers correlated affect with
aberrant activation in the hippocampus during smoking cue presentation (10) and hippocampal
volume could be correlated with successful quit attempts (11). Thus, the hippocampus plays an
important role in the anxiolytic effects of nicotine and nicotine-withdrawal associated negative affect
in both humans and animal models.

We had shown previously that the transcription factor CREB is required for nicotine reward (12),
and through genomic analyses identified the AMPK pathway as one CREB target following chronic
nicotine exposure and withdrawal (13). We discovered that within the hippocampus, CREB binding
was enriched in a number of pathways (Ingenuity Pathway Analysis, see (13) for complete gene
lists). In the category of “cell-to-cell signaling, carbohydrate metabolism, lipid metabolism”, we
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found that CREB binds to the cis-regulatory elements in 12 of 24 members of the energy-sensory
AMPK (AMP-activated protein kinase) pathway as listed in the Reactome Database (Table 4.1).
These included several subunits of AMPK itself (the genes encoding the β1, β2, γ1 and γ2 subunits)
and the upstream regulator of AMPK, LKB1 (Liver Kinase B1; also known as Serine/Threonine
Kinase 11, STK11).

Although the role of AMPK in peripheral tissues is well established, few studies have focused on
its effect within the central nervous system, and none have examined its relation to nicotine
dependence, outside of the hypothalamus (14). Of importance, recent studies illustrate that AMPK
signaling is functionally linked to behavior including cognition and negative affect (15-17) and these
behaviors contribute to relapse during nicotine withdrawal. Therefore, we wanted to determine if
controlling AMPK activity during nicotine withdrawal could ameliorate affective symptoms of
nicotine withdrawal.

Results
First, we evaluated the effects of chronic nicotine and 24-hour withdrawal on AMPK pathway
activation in the brain. Nicotine treatment caused a significant activation of the pathway in the
hippocampus, as shown by the elevated pAMPK/AMPK ratio and the increased phosphorylation of
the AMPK target ACC (acetyl-CoA carboxylase; Fig. 1A, B). Of interest, this is the only brain region
examined that shows this pattern of pAMPK activity (Fig S4.1). Next, we determined whether
pharmacologic activation of the AMPK pathway could ameliorate nicotine withdrawal symptoms.
To this end, we treated mice with AICAR, an allosteric activator of AMPK (18). The drug caused a
significant activation of the AMPK pathway in the hippocampus, indicating that it crosses the blood
brain barrier (Fig. 4.1C). Nicotine withdrawal causes anxiety-like behaviors in mice, which can be
evaluated using two behavioral tests, novelty-induced hypophagia and marble burying. A reduction
in anxiety-like behavior was measured by a reduction in latency to feed, and a reduction in number
of marbles buried in the novelty-induced hypophagia and marble burying tests, respectively. In both
assays, AICAR treatment completely abolished the effects of nicotine withdrawal (Fig. 4.1 D, E).
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Next, we employed the FDA-approved diabetes drug metformin, which targets AMPK activation in
the liver (19, 20). One week of systemic metformin pre-treatment resulted in activation of the AMPK
pathway following nicotine withdrawal compared to saline-pretreated animals (Fig. 4.2A-C).
Strikingly, systemic metformin also completely prevented anxiety-like behaviors caused by nicotine
withdrawal (Fig. 4.2D, E) at a dose that did not impact body weight, food consumption, or glucose
levels under fed or fasted conditions (Fig. S4.2). Of note both AICAR (Fig. 4.1D), as well as
metformin (Fig. 4.2D) reduced latency to feed in the NIH in naïve mice suggesting activating AMPK
may provide a novel target for general anxiolytic activity as well as anxiety-induced from nicotine
withdrawal.

Metformin is known to have multiple peripheral targets, including liver and skeletal muscle, and
activation of the AMPK pathway in these organs might indirectly contribute to behaviors observed
following withdrawal from nicotine. To determine if metformin acts centrally to improve nicotine
withdrawal symptoms or if peripheral effects contribute, we implanted mice with osmotic minipumps
connected to intracerebroventricular (i.c.v.) guide cannulas to centrally deliver either metformin
(50μg/day) or saline for one week prior to withdrawal. This dose of i.c.v. metformin was chosen
because it does not alter peripheral glucose metabolism ((21) and Fig S4.2). As expected, seven
days of i.c.v. metformin caused AMPK activation in the hippocampus but not in the liver (Figure
4.3A, B). Importantly, centrally administered metformin completely prevented nicotine withdrawal
induced anxiety behaviors, as shown by reduced latency to consume novel food (Figure 4.3C).
These data strongly support the notion that central, not peripheral, actions of metformin ameliorate
nicotine withdrawal symptoms.

Metformin has been shown to activate a variety of cellular targets in addition to AMPK (19, 20, 2224). In order to confirm that AMPK is the relevant target of metformin-mediated reduction of anxietylike behaviors following nicotine withdrawal, we employed Ampkα1loxP/loxP; Ampkα2loxP/loxP mice
harboring conditional alleles for both a-subunits of AMPK (abbreviated in the following as
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AMPKαloxP/loxP). An adeno-associated virus (AAV) encoding Cre recombinase (AAV-Cre) was
microinjected directly into the dorsal and ventral hippocampus of AMPKαloxP/loxP mice generating
site-specific deletion of AMPKα (Fig. 4.4A). To assess the anatomical and temporal resolution of
our injection coordinates, AAV-GFP (green fluorescence protein) was injected into the
hippocampus of AMPKαloxP/loxP mice and its presence in the expected location confirmed eight
weeks later through GFP immunohistochemistry (Fig. 4.4A). Western blot analysis confirmed that
total levels of AMPKα were decreased in the hippocampus 8-weeks following AAV-Cre injection in
AMPKαloxP/loxP mice, but remained unchanged in other brain regions such as the cortex (Fig. 4.4B).
Further, levels of pACC, were also reduced in the hippocampus demonstrating a functional
reduction in the pathway (Fig. 4.4B).

To assess anxiety-like behaviors, mice were trained in the NIH paradigm four weeks following
intrahippocampal injection of AAV-Cre, and tested eight weeks post viral injection to ensure full
AMPK ablation (Fig. 4.4C). Mice were treated with nicotine and metformin for one week, followed
by 24 hours of nicotine withdrawal before behavioral testing. As shown in Figure 4.4D, AMPKdeficient mice treated with metformin showed a dramatic and significant increase in the latency to
feed on the novel food relative to nicotine-treated mice, indicating that the positive effects of
metformin on nicotine withdrawal-induced anxiety are mediated, at least in large part, by the
presence of AMPK in the hippocampus.

Discussion
Multiple preclinical and clinical studies have explored the influence of targeting nicotinic
acetylcholine receptors (nAChRs) for smoking cessation therapies. However, the limited success
and adverse side effects of these aids call for investigation beyond targeting nAChRs to abrogate
nicotine withdrawal symptoms such as negative affect. Here, we have used pharmacological,
behavioral, and genetic approaches to identify central AMPK activation as a potential novel
therapeutic approach for nicotine cessation therapy.
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Withdrawal from nicotine produces physiological, affective and cognitive effects (25, 26). The
negative affect experienced during withdrawal is directly associated with early smoking relapse,
with successful quitters exhibiting greater positive affect as compared to those that relapse (27).
Smokers also report that one of their top concerns when considering the consequences of
abstinence is the loss of nicotine as a tool to cope with negative affect (28).

To mechanistically examine the anxiogenic effect of nicotine withdrawal in preclinical models, we
used behavioral paradigms that reliably demonstrate the anxiety impairments observed in humans
following withdrawal. The novelty-induced hypophagia (NIH) test and marble burying test (MB) are
two validated tests to evaluate anxiety-like behavior in rodents. Chronic nicotine reduces anxietylike behavior as measured by a decreased latency to eat a palatable food in a novel environment
in the NIH test. In contrast, latency is significantly increased following nicotine withdrawal (13, 29,
30). Similarly, chronic nicotine decreases anxiety-like behavior as measured by a reduction in the
number of marbles buried while withdrawal increases the number of marbles buried in the MB test
(6, 29).

Based on our findings demonstrating the preclinical efficacy of metformin in alleviating anxiety-like
behavior following nicotine withdrawal, we propose that AMPK activation in the brain via metformin
could be repurposed as a novel pharmacotherapy for nicotine cessation. The proven preclinical
efficacy of metformin in alleviating withdrawal symptoms along with its well-established safety
profile for diabetes treatment should encourage investigators to translate these findings into future
clinical trials for higher continuous abstinence rates in smokers with the added benefit of
normalizing glycemic control.

Materials and Methods
Study Design
The aim of this study was to examine the impact of AMPK activation on mediating anxiety-like
behavior and cognition in preclinical models of nicotine withdrawal. To this end, mouse studies
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were conducted where mice received osmotic minipumps containing saline or nicotine
(18mg/kg/day) for two weeks. Spontaneous withdrawal from nicotine occurred following physical
removal of minipumps. All behavioral responses were measured between 24-48 hours of
withdrawal as the first two days of nicotine withdrawal are associated with the highest rate of
relapse in humans (31) and with peak affective withdrawal symptoms in mice (32). AMPK activators
(AICAR and Metformin) were chronically administered prior to withdrawal from nicotine, and
behavioral outcomes evaluated using two behavioral paradigms: novelty-induced hypophagia
(NIH) and marble burying (MB). Experimenters blind to treatment groups measured behavioral
endpoints; latency to consume (NIH) and number of marbles buried (MB). Western blotting was
used to quantify protein levels of AMPK within hippocampal tissue following AICAR or Metformin
administration.

Finally,

we

used

an

AAV

vector

to

deliver

Cre

recombinase

into

Ampkα1loxP/loxP;Ampkα2loxP/loxP mice harboring a conditional allele for AMPK to determine if AMPK
is necessary for mediating the anxiolytic effects of Metformin during withdrawal from nicotine.

Animals
Male 129SvEv;C57Bl/6J F1 hybrid mice 6-8 weeks of age were obtained from Jackson
Laboratories and used in behavioral paradigms, i.c.v. drug experiment, and molecular studies. All
AAV-Cre experiments were conducted in previously derived and described AMPKαloxP/loxP mice
(AMPKα1loxP/loxP mice previously crossed with AMPKα2loxP/loxP mice) (23, 33) from Dr. Benoit
Viollet’s lab (Institut Cochin, INSERM). All mice were maintained on a standard light cycle (lights
on between 0600 and 1800 h) and had free access to food and water. All experimental procedures
were approved by the University of Pennsylvania Animal Care and Use Committee and were in
compliance with the National Institute of Health Guide for the Care and Use of Laboratory Animals.

Nicotine: delivery, dose, and withdrawal
Mice were anesthetized with an isoflurane/oxygen mixture (1-3%), and osmotic minipumps (model
1002, Alzet) were placed subcutaneously using aseptic surgery techniques. (-)-Nicotine hydrogen
tartrate salt (MP Biomedicals) was dissolved in sterile 0.85% saline and administered in osmotic
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minipumps at a dose of 18mg/kg/day (dose expressed as the freebase weight) for two weeks.
Control (saline-treated) mice received osmotic minipumps filled with 0.85% saline. Following
treatment, minipumps were surgically removed from one half of mice receiving saline and from
mice treated chronically with nicotine to initiate spontaneous withdrawal.

In Vivo Drug Treatments
Metformin (Spectrum) was dissolved in saline and administered at 250 mg/kg by i.p. injection.
AICAR (Toronto Research Chemicals) was dissolved in saline and administered at 500 mg/kg by
i.p. injection. Vehicle was .85% saline administered by i.p. injection. All injections started 7 days
prior to withdrawal from nicotine and were given once a day between 9-10AM.

Intracerebroventricular administration of Metformin
Osmotic minipumps (model 2002, Alzet) for i.c.v. delivery were filled with either 0.85% saline or
Metformin (50μg/day), connected to silicone tubing (CT24SR, PlasticsOne), push-fit into guide
cannula (3300/SP, PlasticsOne), and allowed to equilibrate to 37°C overnight. One week after mice
were implanted with nicotine minipumps, mice were again anesthetized with vaporized isoflurane.
The minipump containing Metformin or 0.85% saline was inserted contralateral to the nicotine
minipump, and the guide cannula was placed above the right lateral ventricle (anteroposterior, -0.8
mm; mediolateral, +1.5 mm) and fixed with dental cement. Six days after the surgery nicotine
minipumps were removed, and behavioral testing occurred at a 24-hour withdrawal timepoint.

Western Blotting
Protein analysis was performed as previously described (34, 35). Briefly, tissue was lysed in 50mM
Tris (pH 7.4), 150mM NaCl, 1% Triton X-100, 15% glycerol, phosphatase inhibitor cocktail 2 and 3
(sigma), and protease inhibitor cocktail 1 and 2 (Roche). Equal amounts of protein were run on
NuPage 4-12% Bis-Trisgels (Invitrogen). Following SDS-PAGE, and blocking, membranes were
incubated overnight at 4°C with one of the following antibodies from Cell Signaling Technologies:
AMPK, phospho-AMPKα, ACC, phospho-ACC or GAPDH. Antirabbit Ig horseradish peroxidase-
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conjugated secondary antibody (Jackson Immunoresearch Laboratories) and the SuperSignal
West Pico chemiluminescence reagent (Thermo Scientific) were used for detection. Quantification
of the protein was performed using ImageJ software according to their provided protocol. Densities
were calculated for each sample and analyzed across conditions.

Viruses and microinjections
The packaging, purification and determination of vector titers for the Adeno-associated viruses
(AAV9.CMV.PI.eGFp.WPRE.bGH and AAV9.CMV.PI.CRE.rB) were all performed by the University
of Pennsylvania Vector Core. Injection titers and stereotax coordinates were determined as
described previously (36). AAV-Cre or AAV-GFP virus was stereotaxically microinjected into the
dorsal and ventral hippocampus (anterior-posterior-2.1, lateral +/- 1.4, dorsoventral -2.0; and
anterior-posterior -2.9, lateral +/- 3.0, dorsoventral -3.8) at a final titer of 6.534x1010gc/ul over 20
minutes using a pressure-injection system (KD Scientific) at 0.1ul/min, 5 minutes per coordinate.
Behavioral testing began 8 weeks after surgery to allow time for recovery, and viral expression.

Marble Burying
The Marble burying test was conducted as previously described (6). After 1-hour of acclimation in
the room where marble burying testing was performed, the mice were placed in a small cage
(26x20x14cm) with 5-cm deep bedding, on top of which 20 equally distributed marbles lay. The
mice were left undisturbed for 15 minutes. After 15 minutes, an investigator blind to the treatment
group returned the mouse to its home cage and counted the number of marbles that were buried
in bedding (3/4 or more coverage).

Novelty-Induced Hypophagia
The novelty-induced hypophagia (NIH) test was conducted as previously described (13) with mice
housed in groups of two. Mice were placed in a testing room with dividers separating their home
cage, and allowed to acclimate for one hour prior to presentation of a palatable food (peanut butter
chips; Nestle). Training was repeated over 10-days with latency to consume the food measured on
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days 4-10. Following training, mice were randomly assigned to a treatment group and implanted
with osmotic minipumps. Following treatment, latency to consume peanut butter chips over 15minutes was measured in the home cage as a baseline, and then measured again 24-hours later
in a novel environment. The novel environment consisted of a standard cage with no bedding
placed within a white box with bright light (~2150 Lux) and a novel smell (1:10) pine sol).

Statistical Analysis
All statistical analysis was conducted using GraphPad Prism 5.0 software package (GraphPad
Software), and all data are presented as mean ± standard error of mean. For comparisons
between two groups (e.g., western blot quantification), a Student’s t-test was used. For
comparisons among multiple groups at one time point (e.g., marble burying) a one-way ANOVA
was used. Finally, for comparisons between multiple groups at different time points (e.g., novelty
induced hypophagia), a repeated measures two-way analysis of variance (ANOVA) was used to
determine significant differences with time (Home day, Novel day) representing the withinsubjects, repeated-measures factor, and drug treatment the between-subjects factor. The
threshold for statistical significance was set at P < .05, and Bonferroni multiple comparison tests
were used for all post hoc analysis.
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Tables
Table 4.1. Members of the AMPK pathway bound by CREB in the mouse hippocampus

Gene Symbol

Gene Name

Acacb

Acetyl-CoA carboxylase beta

Acsl1

Acyl-CoA synthetase

Cab39L

Calcium binding protein 39

Ppm1a

Protein phosphatase 1A

Prkab1

AMPK, beta 1 subunit

Prkab2

AMPK, beta 2 subunit

Prkag1

AMPK, gamma 1 subunit

Prkag2

AMPK, gamma 2 subunit

Rheb

Ras homolog enriched in brain

Rptor

Raptor, regulator of MTO

Stk11

Serine/Threonine Kinase 11

Tsc1

Tuberous sclerosis 1
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Figures

Figure 4.1. The AMPK activator AICAR eliminates anxiety-like behaviors following
nicotine withdrawal. (A,B) Nicotine causes activation of the AMPK pathway in the
hippocampus, as indicated by representative Western blot analyses of AMPK, phospho-AMPK
(pAMPK) (n=9), ACC and phospho-ACC (pACC) tissue (n=3). *, P < 0.05, ***, P < 0.001. (CE) Chronic AICAR increases pAMPK in the hippocampus and reduces anxiety-like behavior
during 24-hour withdrawal from nicotine. (C) Systemic AICAR treatment results in significant
activation of the AMPK pathway in the hippocampus, indicating that the drug crosses the blood
brain barrier (n=4; P < 0.05). (D,E) Anxiety-like behavior precipitated by nicotine withdrawal is
reduced by AICAR. (D) Novelty-induced hypophagia (NIH) was tested 24-hours after nicotine
withdrawal. AICAR prior to nicotine withdrawal prevented the increase in latency to feed
observed in saline-treated mice undergoing 24-hour withdrawal. Bars represent mean latency ±
SEM (n=7-13),* P <0.05, ** P < 0.01. (E) Marble burying was tested 48-hours after nicotine
withdrawal. Data represent the mean number of marbles buried over 15 minutes ± SEM (n = 78), ** P < 0.01.
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Figure 4.2. Systemically administered metformin increases hippocampal pAMPK and
reduces anxiety-like behavior during nicotine withdrawal. (A-C) Western blot analysis of
hippocampal AMPK, pAMPK, ACC, and pACC levels following 24-hour nicotine withdrawal in
the presence and absence of i.p. Metformin. n=6-7; **, P < 0.01; ***, P < 0.001. (D) Mice
chronically treated with nicotine exhibited a reduced latency to approach a palatable food in a
novel environment compared to 24-hour withdrawal mice. Metformin reverses the increase in
anxiety-like behavior caused by nicotine withdrawal. Bars represent mean latency ± SEM (n =
13-15), * P < 0.05, ** P < 0.01. (E) Metformin treatment reduced anxiety-like behavior as
measured by the number of marbles buried. Data represent the mean number of marbles
buried over 15 minutes ± SEM (n = 7-16), * P < 0.05.
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Figure 4.3.
Intracerebroventricular (i.c.v.) metformin activates hippocampal AMPK
levels and reduces nicotine withdrawal symptoms. (A,B) Western blot analysis
demonstrates increased hippocampal (A) but not hepatic (B) pAMPK following one-week of
i.c.v. administration metformin compared to mice administered i.c.v. saline following nicotine
withdrawal. n=4 ; *, P < 0.05. (C) Metformin given i.c.v. prevents anxiety like withdrawal
symptoms precipitated by nicotine withdrawal as determined by NIH paradigm, as seen by
reduced latency to feed during 24-hour withdrawal compared with mice administered saline.
Bars represent mean latency ± SEM (n = 7-8), * P < 0.05, *** P < 0.001.
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Figure 4.4. Anxiolytic effects of metformin during nicotine withdrawal are dependent on
hippocampal AMPKα. (A) Representative GFP expression in the hippocampus at 10x
magnification. From L to R: GFP, DAPI, merge. (B) Western blot analysis of AMPKα and pACC
in the hippocampus and cortex of AAV-Cre treated AMPKαloxP/loxP mice indicates the specificity
of gene ablation. (C) Overview of experimental paradigm for novelty-induced hypophagia (NIH)
test. Two month-old AMPKαloxP/loxP mice were injected sterotactically with AAV-Cre. Four weeks
later, mice were trained for the NIH test, treated with chronic nicotine, and NIH behavior
examined 24-hours following withdrawal from nicotine. (D) Chronic Metformin treatment does
not reduce anxiety in AMPKαloxP/loxP mice injected with AAV-Cre, evidenced by an increased
latency to consume a palatable food in a novel environment during 24-hour withdrawal
compared to nicotine-treated AMPKαloxP/loxP mice injected with AAV-Cre. Bars represent mean
latency ± SEM (n = 6-7), ** P < 0.01.
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Supplementary Information

Figure S4.1. Relative to untreated conditions, chronic nicotine and nicotine withdrawal do
not significantly alter pAMPK/GAPDH in the striatum, amygdala, or cortex. (A) Chronic
nicotine and nicotine withdrawal have no affect on levels of pAMPK in the striatum, as indicated
by Western blot analysis (n=7-8). (B) Relative to chronic nicotine, 24-hour nicotine withdrawal
significantly upregulates pAMPK in the amygdala. Neither chronic nicotine or nicotine withdrawal
significantly alter pAMPK/GAPDH compared to untreated controls (n=8). *, P < 0.05. (C) Chronic
nicotine and nicotine withdrawal have no affect on levels of pAMPK in the cortex (n=8).
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Figure S4.2. Systemically administered metformin has no effect on body weight, food
consumption, or glucose levels under fed or fasted conditions. (A) Mice treated with 7 daily
injections of i.p. metformin show no differences in body weight compared to saline-injected mice
(n=8-9). (B) Metformin treatment has no effect on the amount of a palatable food consumed in the
home cage environment or in a novel environment. Chronic nicotine and withdrawal also have no
effect on consumption (n=8). (C) Metformin treatment has no effect on fed or fasted glucose
levels in mice undergoing nicotine withdrawal. Chronic nicotine and withdrawal also have no
effect on glucose levels (n=7-9). Across conditions, glucose levels were lower under fasted
conditions compared to fed conditions. ****, P < 0.0001. Bars represent mean latency ± SEM.
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CHAPTER 5: General Conclusions and Future Directions
Summary
The studies described in this dissertation utilize mouse models to investigate how and why
changes in the brain occur following exposure to substances of abuse. The first study (Chapter 2)
describes a systems-level approach to characterizing changes in the functional organization of
the brain following chronic opiate exposure. We seek to go beyond the descriptive power of graph
theoretical approaches by applying a control theoretic approach to determine how the brain
transitions from one dependence-associated activity state to another—which regions of the brain
drive these transitions? We determine that coexpression of plasticity-related genes predicts
changes in functional associations between brain regions following opiate dependence, and that
regions of the midbrain, hippocampus and striatum are most influential in driving opiate-induced
brain state transitions (1).

Further work will be necessary to evaluate the therapeutic potential of modulating neuronal
activity within regions of the brain that drive state transitions. In order to accomplish this, future
studies should seek to directly link changes in brain state with changes in behavior. The use of a
rodent self-administration model would enable the association of changes in connectivity with the
transition to compulsive drug-seeking behavior that is characteristic of SUDs. Chemogenetic or
optogenetic silencing approaches could be applied to test the hypothesis that inhibiting neuronal
activity within potential control points in the brain will hinder the transition from an opiate-naïve to
an opiate-dependent brain state and disrupt the development of addictive behaviors.

In Chapter 3, we investigate the influence of a genetic variant on opiate reward. The SNP D398N
in the gene CHRNA5, which encodes the a5 nAChR subunit, has been associated with increased
risk for substance use disorders. In this study, we provide evidence that this genetic variant
enhances opiate reward two weeks after morphine exposure in female mice. This difference in
phenotype may be driven by morphine-induced changes in dopaminergic cellular physiology in
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the VTA that are evident 24 hours after repeated morphine exposures in the CPP paradigm.
Further work in this area could benefit our understanding of how genetic variation in CHRNA5
impacts substance abuse liability.

The third study described in this dissertation (Chapter 4) examines the role of AMP-activated
protein kinase (AMPK) in nicotine dependence and withdrawal. We demonstrate that modulating
AMPK expression by administering metformin, an AMPK activator, attenuates anxiety-like
behaviors that are associated with nicotine withdrawal. We further provide evidence that
anxiolytic effects of metformin depend upon expression of AMPK within the hippocampus (2).
This finding may have important therapeutic implications, as metformin could potentially be
repurposed for the treatment of nicotine withdrawal symptoms if it is found to reduce these
symptoms in humans.

General limitations
A number of limitations are broadly relevant to the studies described in this dissertation and
warrant further discussion. Each of the studies described herein utilize passive methods of drug
administration, including experimenter-administered injections and osmotic minipumps which are
implanted subcutaneously. As such, these studies fail to capture the motivational aspects of
voluntary drug-taking behavior that are associated with SUDs. On the other hand, rodent models
of physical dependence have high construct validity in that they demonstrate comparable
withdrawal phenotypes to those observed in humans, including both physical and affective signs.
Further, experimenter-administered drug exposure ensures that drug treatment is reproducible
across experiments and treatment conditions, allows for consistent administration of drug doses
across subjects, and allows for precise control over the termination of chronic drug exposure.

Age and sex represent two biological variables that are not fully accounted for in these studies. In
general, age is often underreported or overlooked in preclinical rodent studies (3). The
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experiments described in Chapter 2 were carried out exclusively in eight-week-old male mice,
and six- to eight-week-old mice were used for the experiments in Chapter 4. Though mice are
sexually mature by eight weeks of age, developmental changes in the central nervous system are
still ongoing (4). Both developmental processes and changes in brain plasticity associated with
aging could impact the extent or persistence of drug-induced changes in neural connectivity.
Further, aging is also associated with altered expression of genes encoding key liver enzymes (3,
5, 6). Changes in drug metabolism over the course of the lifespan could impact behaviors
relevant to drug abuse as well as the response to pharmacotherapies for addiction. It should
therefore be noted that the translational relevance of these studies may be limited to young
individuals.

Studies in humans and rodent models suggest sex differences in drug abuse liability (7-11). The
studies described in chapters 2 and 4 included only male mice, and thus the findings of these
studies may not be relevant to females. In Chapter 3, we assessed morphine reward in male and
female mice and identified a sex-specific effect of Chrna5 genotype on reward behavior;
electrophysiology and immunohistochemistry studies were then carried out exclusively in
females. Repeating these experiments in males would be useful to confirm the sex-dependence
of the results and their relevance to the behavioral phenotype observed exclusively in females.

The studies described in Chapter 4 employ two measures of affective behavior: marble burying
and novelty-induced hypophagia (NIH). The affective states modeled by these behavioral
paradigms have been a subject of debate in the literature. For example, marble burying has been
used as a measure of anxiety, perseverative behavior, obsessive-compulsive disorder, impulsivity
and dementia (12-15). NIH has been used as a measure of both anxiety-like behavior and
antidepressant response (16). Behavior in the NIH assay could also be influenced by motivation
to feed, which may be sensitive to nicotine treatment and withdrawal; while nicotine may reduce
food intake, nicotine withdrawal is associated with increased appetite (17, 18). Thus, the
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interpretability of these behaviors may be limited. This limitation is mitigated somewhat by the use
of multiple assays to assess a single phenotype.

In Chapter 2, we use the immediate early gene (IEG) FOS as a marker for neuronal activity. FOS
has been widely used in preclinical studies to identify neural substrates of drug abuse (19, 20).
However, a limitation of using FOS alone is that it is expressed at very low levels basally; thus,
our study is biased toward detecting only increases in neuronal activity after opiate exposure.
Other IEG markers of neuronal activity, such as Egr-1 (zif268), are expressed at higher levels
than FOS basally and could be used to detect inhibition of neuronal activity following a drug
stimulus (21).

With respect to data analysis, another limitation of this work relates to the use of a systems
engineering approach to address changes in brain state following chronic drug exposure. The
control theoretic approach employed in Chapter 2 assumes structural invariance across time;
however, long-term drug exposure may induce changes in the brain’s white matter connectivity
that are not accounted for by this model. While fixed structural connections may constrain
neuronal activation patterns over transient time scales, over longer time scales the relationship
between structure and function is bidirectional, such that neuronal activity also serves to
modulate structural connectivity.

The future of animal models of substance use disorders
Over the course of the last several decades, preclinical addiction research in rodent models has
provided considerable insight into the neurobiology of substance use disorders. Despite this, little
progress has been made toward the development of more effective treatments and preventative
measures for addiction. The failure to translate findings from preclinical animal models into
improved clinical approaches has led some to argue that addiction may be a uniquely human
phenomenon that cannot be modeled in rodents (22, 23). Though it may not be possible to model
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all features of SUDs in rodents, these models can nonetheless provide valuable insight and
contribute to improved treatment outcomes. In the remainder of this section, I will discuss
potential barriers to the utility of animal models for understanding and treating SUDs and future
opportunities.

Modeling substance use disorders in rodents
Ultimately, animal models of addiction and other neuropsychiatric conditions serve to fill gaps in
our understanding of the human condition. In the context of substance use disorders, they offer a
controlled environment in which to probe the effects of genetic and environmental risk factors in
isolation. They allow for the study of the transition from initial drug exposure to drug dependence,
which is generally not possible in human studies, and for the mechanistic examination of specific
circuitry and molecular targets in addictive processes.

Some limitations associated with rodent models of addiction are inherent to the inability to model
or assess higher-level cognition. For instance, continued substance use despite the desire or
intent to stop is a hallmark of substance use disorders that cannot be modeled in rodents.
Modeling continued drug use in the face of negative consequences is challenging in an organism
that is unable to learn associations between events separated in time by more than a few
minutes. Attempts to model negative consequences, for example by introducing a shock or bitter
flavor during drug self-administration, may not be analogous to the longer-term consequences
associated with SUDs in humans, such as job loss and disrupted social relationships. Finally,
social influences are known to play a role in drug abuse initiation and relapse liability but may be
difficult to model in rodents.

Modeling addiction in rodents also necessitates assumptions about why rodents engage in
particular behaviors. Though rodent models of self-administration are high in face validity, this
could be attributable to anthropomorphic interpretation of the animals’ behavior (24). Drug
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seeking and escalating drug intake appear similar in humans and rodents, but the underlying
causes for the behavior may not be the same (25).

Recent developments in rodent behavioral models have begun to place greater emphasis on
ethological relevance (26-28). Data-driven approaches that seek to uncover the neural substrates
of innate rodent behavior may prove useful in developing novel models of addiction and other
disorders. In the context of rodent models of substance abuse, rather than attempting to map
human behaviors onto rodent models, an approach that instead seeks to delineate the animal’s
response to drugs in a naturalistic context could prove fruitful. Such approaches could also
overcome challenges associated with the interpretation of traditional rodent models of affective
behavior. Advances in our ability to record and interpret rodent vocalizations may also provide
deeper insight into their social behavior and its role in SUDs (29, 30).

Translational approaches to data analysis
In addition to limitations inherent to using animal models, differences in data analysis and
interpretation serve as barriers in the translation of findings from animal studies to humans.
Rodent models enable the study of cellular and molecular mechanisms in the context of simple
circuits, while the study of the human brain generally necessitates a systems-level approach. The
integration of findings across these scales could be extremely powerful but is currently an
obstacle in the translation of findings from one to the other. To this end, it will be important to
address questions relevant to translation of neural data across species and modalities. For
instance, how might we resolve temporal differences in blood oxygen level-dependent (BOLD)
signal, the usual readout of brain activity in human studies, and expression of molecular markers
used as proxies for neuronal activity in animal models? Recent technological advances are now
enabling the collection of whole-brain data with cellular resolution. The research described in
Chapter 2 illustrates the value of using systems approaches to understand large-scale datasets
from animal models, and the future holds tremendous potential for further work in this area.
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Abstract
Current estimates indicate that millions of people in the United States abuse opioid drugs, which
may also affect their offspring. To determine whether parental exposure to morphine alters
reward and affective behaviors in subsequent generations we exposed male and female
C57BL/6NTac mice to morphine (75 mg) or placebo pellets for 4 weeks. Naïve mice were used
as mating partners to create subsequent generations (F1 and F2). Adult male and female F1 and
F2 mice were tested in the morphine conditioned place preference paradigm (CPP), marble
burying (MB), acoustic startle response (ASR), and open field tests (OFT). Paternal morphine
exposure resulted in significantly attenuated preference scores amongst F1 male offspring, but
significantly higher preference scores amongst F1 female offspring at the lowest CPP dose tested
(5 mg/kg). In contrast, maternal exposure to morphine did not affect morphine reward in the F1
generation; however, the F2 male offspring of morphine-exposed F0 females displayed
significantly higher CPP preference scores. Preference scores in F2 females were not affected by
F0 male or female morphine exposure. Sex-specific alterations in affective behaviors were
observed only in the offspring of F0 males exposed to morphine with F1 males spending less time
in the center of the open field and F1 females spending more time in the center of the open field.
One generation later, affective behaviors were no longer altered in F2 males but F2 females from
the F0 male morphine exposure buried more marbles in the MB test. In summary, early exposure
to morphine in males and females causes lineage-specific inheritance of reward and affective
behaviors.
Key Words: morphine, opioid, transgenerational, reward, affective behavior, sex differences

112

1. Introduction
Opioid use disorders have reached epidemic-like proportions in the United States. Drug overdose
is now the leading cause of accidental death in the US, and opioid overdose accounts for the
largest proportion of these deaths [1]. As rates of opioid abuse increase, the potential for risk to
subsequent generations also increases. A growing body of literature indicates that parental
exposure to opioids may impact behaviors relevant to drug abuse risk in their offspring.

Preclinical animal studies have identified specific behaviors pertaining to opiate reward, selfadministration, affect, and cognition that are impacted by parental opioid use, in the absence of
direct in-utero exposure [2-5]. To date, most studies that have examined the effects of
preconception opioid exposure on subsequent generations have administered 10 days of
escalating doses of morphine to adolescent [2-4,6-10] or adult [11] male and female rats that
were subsequently mated with naïve partners. Recently, transgenerational effects of paternal
morphine self-administration have also been investigated [5].

Despite the growing number of published studies, there is no clear consensus on the
transgenerational effects of opioid exposure on affective behavior. For example, both male [12]
and female [6] offspring of mothers that were exposed to morphine during adolescence exhibit
increased anxiety-like behavior in the elevated plus maze, but females also show reduced
anxiety-like behavior in the open field [7]. Li et al. (2014) observed increased anxiety-like
behavior, examined in the elevated zero maze and open field, in male and female offspring if
either or both parents were exposed to morphine during adulthood. In contrast, Ellis et al. (2020)
observed no effect of paternal morphine exposure on anxiety-like behavior in the defensive probe
burying and novelty-induced hypophagia paradigms, although they did identify impaired novel
object recognition in female offspring [5].
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In addition to affective behaviors, parental morphine exposure has been shown to impact
morphine sensitivity in the offspring in a sex-dependent manner. Specifically, female offspring of
morphine-exposed mothers are more sensitive to the acute locomotor activating effects of
morphine, while males demonstrate more robust morphine sensitization [6]. In addition, there are
sex-dependent differences in the sensitivity to the rewarding effects of morphine in the F1
offspring of male [9] and female [2] rats that were exposed to morphine during adolescence and
later mated with naïve partners as adults. Specifically, F1 female offspring of mothers that were
exposed to morphine are more sensitive to the rewarding effects of morphine [2]; in contrast, F1
male offspring of morphine-exposed fathers show attenuated morphine place preference [9].

The purpose of this study is to extend the current literature by examining effects of maternal and
paternal morphine exposure in mice on reward and affective behaviors in subsequent
generations. While a number of studies have identified behavioral effects of parental opiate
exposure, it remains to be determined whether altered phenotypes persist beyond the F1
generation. Further, in contrast to most prior studies, we examined the impact of both maternal
and paternal morphine exposure on both male and female offspring within the same generation,
thus avoiding potential cohort effects. We used the conditioned place preference (CPP) paradigm
to assess sensitivity to morphine reward in both the F1 and F2 generations following F0 morphine
exposure. In addition, the marble burying task, acoustic startle response, and open field test were
used to measure affective behavior. Based on previous findings, we hypothesized that maternal
and paternal exposure to morphine would lead to sex-dependent alterations in reward and
affective behaviors in the F1 and F2 offspring.

2. Materials and Methods

2.1.

Drugs
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Morphine (75 mg base) and placebo (cellulose) pellets were acquired from NIDA Drug Supply
Program (Research Triangle Park, NC) and used for chronic F0 exposure. Morphine sulfate
(NIDA Drug Supply Program) was dissolved in saline and used for the conditioned place
preference experiments.

2.2.

Animals

The F0 mice used in this study were generated by breeding C57BL/6NTac mice (Taconic,
Hudson, New York) at the University of Pennsylvania for 2 generations in order to eliminate
potential effects of stress due to shipping and acclimation to the animal facility conditions [13]. All
mice were group housed (3-5/cage) with ad libitum access to food and water under a 12-hour
light/dark cycle (lights on at 0700). All behavioral testing occurred during the light phase of their
cycle. All procedures were approved by the University of Pennsylvania Animal Care and Use
Committee and were in compliance with the National Institutes of Health Guide for the Care and
Use of Laboratory Animals.

2.3.

F0 exposure

F0 male mice were implanted with either a morphine pellet (n = 11) or placebo pellet (n = 11) on
postnatal day (PND) 28 under isoflurane anesthetic. In pilot studies morphine was undetectable in
serum after 14 days (Morphine ELISA Kit, MyBioSource); therefore, on PND 42 (day 14 of
exposure) the original pellet was removed and a second pellet was implanted to ensure a total of
4 weeks of morphine or placebo exposure. F0 female mice underwent the same exposure
paradigm, except that the initial pellet implantation was delayed by 2 weeks due to the high
mortality rate when exposed earlier. Thus, the first morphine pellet (n = 10) or placebo pellet (n =
7) was implanted on PND 42 and the second pellet was implanted on PND 56 in F0 females. In
order to generate sufficient offspring for breeding and behavioral testing, two cohorts of F0 males
and females were exposed to morphine or placebo and were mated as described below.
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2.4.

F0 mating

Males and females were mated at different times after the morphine exposure to account for
reproductive differences that would impact the transmission of any germline epigenetic alterations
induced by chronic morphine exposure. In females, by 6 weeks of age (sexual maturity in the
mouse) each ovary contains all the oocytes it will produce, albeit at different stages of maturity. In
contrast, spermatogenesis is a continuous process throughout the lifetime of the mouse [14].
Therefore, at the end of the exposure period, F0 males were immediately housed with naïve
females for 1 week to facilitate elimination of sperm that may have been produced prior to
exposure. F0 males were then mated with a new naïve female each week for up to 4 weeks in
order to maximize the F1 offspring generated by each male. F0 females were mated with naïve
males immediately following the exposure period. Naïve males were removed after impregnation.

All F1 offspring were weaned at 28 days and aged in the colony. Mice were weaned at 28 days of
age in order to avoid any adverse effects of earlier weaning on performance in the behavioral
assays [15,16]. Adult (PND 70-84) male and female F1 offspring were used for behavioral studies
or were mated with naïve partners to create the F2 generation. Importantly, F1 mice conceived at
each of the 4 weeks of F0 male exposure were randomly distributed across all behavioral testing
groups and used for mating. No differences were observed in behaviors due to the week of
conception, suggesting that morphine exposure impacted all spermatogonia that differentiated
into sperm equally.

2.5.

F1 mating

F1 mice from the F0 male exposure (n = 3 males and n = 6 females per treatment group) and F1
mice from the F0 female exposure (n = 8 males and n =9 females per treatment group) were
mated with naïve partners and separated after impregnation. All fertile F1 animals were mated
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twice to create a large enough F2 generation for behavioral testing. F2 offspring were weaned on
PND 28 and behavioral testing began in adulthood (PND 70-84).

In this study, male lineage refers to the F1 males and their F2 offspring, both male and female,
and female lineage refers to the F1 females and their F2 offspring, both male and female.

2.6.

Morphine conditioned place preference

Morphine reward was assessed in F1 male and female mice using an unbiased conditioned place
preference paradigm, as described previously [17]. During the pre-conditioning session and test
sessions, mice were allowed to explore both sides of an unbiased two-chambered CPP
apparatus (20 × 20 × 20 cm/chamber) for 900 s, and time spent in each side was recorded.
Beginning on day 2, animals were conditioned once daily for 6 days, with each group receiving
either 5 mg/kg (n = 6-16/group) 10 mg/kg (n = 9-13/group), or 20 mg/kg (n = 8-10/group)
morphine on one side and saline on the other side. Drug-paired sides were randomized among
groups.

The CPP test was performed one day after the last conditioning session. The preference score
for each mouse was determined by subtracting the time spent in the saline-paired side from time
spent in the drug-paired side at pre-conditioning and post-conditioning tests, and then subtracting
the pre-conditioning preference from the post-conditioning preference. Due to a limited number of
F1 animals from the F0 female exposure, in order to achieve sufficient statistical power to detect
an effect of F0 exposure, only 2 doses of morphine were used for conditioning: 5 mg/kg (n = 1113/group) and 10 mg/kg (n = 11-13/group).

F2 male and female mice from the F0 male and female lineages were also tested in the CPP
paradigm. A limited number of animals were available in this generation; therefore, we tested only
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the lowest (5 mg/kg; n = 8-15) and highest (20 mg/kg; n = 7-11/group) morphine doses to
evaluate reward from the F0 male exposure. Only the lowest dose of morphine (5 mg/kg; n = 1322) was used to test CPP in the F2 offspring from the F0 female exposure experiment due to
restricted number of subjects.

2.7.

Marble burying

The marble burying test was performed in F1 (n = 12-16/group) and F2 (n = 17-28/group) mice as
previously described [18]. Briefly, 20 marbles were evenly distributed in rows of 4 atop 5 cm-deep
bedding in a standard mouse cage (26x20x14cm). Mice were acclimated to the testing room for 1
hour and then individually placed into a test cage for 15 minutes. After the test, mice were
removed and an experimenter blinded to treatment condition recorded the number of marbles
buried ¾ or more in the bedding.

2.8.

Acoustic startle response

Reflexive stress response to an unexpected tone was assessed using the acoustic startle
response (ASR) in F1 (n = 10-16/group) and F2 (n = 9-28/group) mice. After a 1 hour period of
acclimation to the behavioral suite, animals were placed in acoustic startle chambers (SR-Labs,
San Diego, CA, USA) for behavioral testing. The chambers consist of a light- and soundattenuating outer plastic box and an inner non-restrictive plastic cylinder chamber affixed to a
stage platform. Broadband acoustic startle tones are emitted from a high-frequency speaker
mounted above the mouse chamber and startle responses are measured by a Piezo Electronics
monitor mounted under the stage platform.

The duration of one testing session was 30 minutes. Animals were first habituated to the inside of
the startle chamber with a 67-decibel sound pressure level (dB SPL) background white-noise for
five minutes. After the habituation period, animals were presented with 10 rounds of 5
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pseudorandom startle tones (50 total trials) of varying dB SPL (75, 80, 85, 90, 95, 100 105, 100,
115, and 120dB SPL). Pseudo random inter-stimulus intervals (ISIs) were generated by the
Startle Response software (SR-Labs; San Diego, CA). Durations of the ISIs were 26, 28, 30, 32,
and 34 seconds. Immediately after startle tone presentation, the startle response was measured
as the average voltage emitted by the piezoelectric pickup per millisecond (ms) for the 100-ms
response window.

2.9.

Open field test

F1 (n = 11-22/group) and F2 (n = 8-27/group) mice were tested in the open field. Activity in the
open field was measured in Plexiglas open field boxes (43x43 cm2) with 32 infrared photobeams
in a 16x16 arrangement using Photobeam Activity System software (San Diego Instruments, San
Diego, CA). The open field was divided into 2 areas: a center area (the innermost 6x6
photobeams) and an outer area that extended from the edges of the center area to the walls.
Mice were placed in the open field close to a wall and allowed to explore for 10 minutes while the
program recorded total distance traveled and time spent in the center area.

2.10. Data analysis

CPP preference scores were compared via 2-way ANOVA, with F0 exposure and morphine
conditioning dose as between-subjects factors. Post-hoc comparisons were Bonferroni-corrected
for multiple comparisons. Only one morphine CPP conditioning dose was used in F2 experiments
from the F0 female exposure; therefore, t-tests were used to compare CPP preference scores of
mice descended from the morphine-treated or placebo-treated F0 generation. Additionally, t-tests
were used to compare number of marbles buried, startle amplitude at 120 dB in ASR, time spent
in the center and total distance traveled in the OFT between mice descended from the morphinetreated or placebo-treated F0 generation. Statistical analyses were performed using Graphpad
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Prism 8 (Graphpad Software, La Jolla, CA) with alpha set at 0.05 (p < 0.05) for all tests. All data
are presented as the mean ± SEM.

3. Results

3.1. Sex-specific transgenerational effects of paternal morphine exposure on rewarding effects
of morphine
To determine whether F0 male exposure to morphine affects the sensitivity of their offspring to
morphine reward, adult F1 and F2 male and female mice were tested in the CPP paradigm.
Lineage-specific effects were analyzed for F2 offspring from F1 males (Fig A1) and females (Fig
A2) separately. F1 male offspring descended from morphine-exposed F0 males displayed
significantly attenuated preference scores (F1, 58 = 5.018, p = 0.0289; Fig A1A). There was no
effect of CPP dose and no dose × exposure interaction. In the F2 generation, we found no effect
of F0 exposure or CPP dose on preference scores of F2 male offspring from the F1 male lineage
(Fig A1B). However, in the F2 female offspring from the F1 male lineage (Fig A1C), there was a
main effect of dose (F1, 37 = 5.463, p = 0.0249) but no effect of F0 exposure or interaction.

In F1 female offspring (Fig A2A), there was a main effect of F0 male exposure (F1, 46 = 7.045, p =
0.0109) and a significant exposure x dose interaction (F2, 46 = 3.436, p = 0.0407). Post hoc
analysis revealed that females whose fathers were exposed to morphine have significantly higher
CPP preference scores at 5 mg/kg morphine as compared to those females whose fathers were
placebo-exposed (t46 = 3.290, p = 0.0058). In the males from the F1 female lineage (Fig A2B),
there was a significant effect of dose (F1, 33 = 5.623, p = 0.0237) and a trend toward a significant
exposure x dose interaction (F1, 33 = 3.762, p = 0.0610). Post hoc analysis revealed that F0
morphine exposure resulted in significantly attenuated CPP amongst F2 males conditioned with 5
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mg/kg morphine (t33 = 2.472, p = 0.0375). In the F2 females from the female lineage (Fig A2C),
there were no significant effects of F0 exposure or CPP dose.

3.2. Sex-specific transgenerational effects of maternal morphine exposure on rewarding effects
of morphine
Lineage-specific effects of F0 female morphine exposure were also analyzed in F2 offspring from
F1 males (Fig A3) and females (Fig A4) separately. In the F1 males (Fig A3A), a 2-way ANOVA
revealed a significant effect of CPP conditioning dose (F1, 40 = 44.26, p < 0.0001), with greater
preference scores in both F0 exposure groups at the higher CPP conditioning dose (10 mg/kg).
There was no effect of F0 exposure and no dose x exposure interaction. However, F0 morphine
exposure increased CPP preference score in F2 males (t26 = 2.175, p = 0.0389; Fig A3B) but not
females from the male lineage.

In F1 females (Fig A4A), 2-way ANOVA analysis of CPP preference scores revealed no
significant main effect of F0 morphine exposure or CPP conditioning dose and no interaction.
Similarly, there was no effect of F0 morphine exposure on CPP preferences scores amongst
males or females of the F2 generation.

3.3. Sex- and lineage-specific transgenerational effects of paternal morphine exposure on
affective behaviors
Affective behaviors were assessed in the marble burying, acoustic startle response, and open
field tests. Lineage-specific effects were analyzed in F2 offspring from F1 males (Table A1) and
F1 females (Table A2) separately. In the male lineage, an effect of parental morphine exposure
on behavior in the OFT was observed only in the F1 males. Specifically, F1 males whose fathers
were exposed to morphine spent significantly less time in the center of the open field as
compared to placebo controls (Table A1; t37 = 2.094, p = 0.0431). Importantly, there was no
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significant difference in total locomotor activity (total distance traveled) in the open field test; thus,
this result cannot be attributed to an effect of parental drug exposure on locomotor activity. F1
females whose fathers were exposed to morphine spent more time in the center of the open field
as compared to those whose fathers were exposed to placebo (Table A2; t31 = 2.376, p =
0.0239); there was no effect on locomotor activity.

In the F2 offspring of F1 males, there was no effect of F0 morphine exposure on marble burying,
ASR, or open field tasks (Table A1). In the F2 males from the F1 female lineage, there was a
trend toward a significant increase in the number of marbles buried (t44 = 1.770, p = 0.0836)
amongst those whose grandfathers were exposed to morphine as compared to placebo controls
(Table A2). In F2 females from the F1 female lineage, there was a significant increase in the
number of marbles buried (t37 = 2.118, p = 0.0409) amongst those descended from the F0 mice
that were exposed to morphine as compared to placebo controls (Table A2).

3.4. No sex- and lineage- specific transgenerational effects of maternal morphine exposure on
affective behaviors
Affective behaviors were also assessed in the F1 and F2 offspring of F0 female morphine
exposure using the marble burying, acoustic startle response and open field tests. Lineagespecific effects were analyzed in F2 offspring from F1 males (Table A3) and F1 females (Table
A4) separately. The number of marbles buried, time spent in the center of the open field, and
startle amplitude were not affected by F0 exposure in F1 males or their F2 offspring (Table A3).
There was, however, a non-significant trend for a decrease in total distance traveled in the open
field test in F2 females from the male lineage F0 female morphine exposure (t29 = 1.794, p =
0.0833). In F1 females and their F2 offspring (Table A4), no differences in any of the affective
behavioral tests were found between F0 female morphine and placebo groups.
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3. Discussion
The current experiments examined the effects of paternal or maternal morphine exposure on
reward and affective behaviors in subsequent generations. Critically, we identified a sexdependent, cross-generational alteration in sensitivity to morphine reward in F1 and F2 offspring.
Following paternal (F0 male) morphine exposure, male offspring of the F1 generation are less
sensitive to the rewarding effects of morphine, while F1 females are more sensitive to the
rewarding effects of morphine. In both instances, this altered reward phenotype was not
transmitted to the F2 generation. In contrast, maternal (F0 female) morphine exposure did not
significantly alter morphine reward sensitivity in males or females of the F1 generation, but in the
F2 generation males exhibited increased sensitivity to rewarding effects of morphine.

Prior studies have identified sex-specific effects of parental morphine exposure on morphine
conditioned place preference and morphine self-administration [2-4,9]. Vassoler et al. (2016)
found no effect of maternal exposure in rats on the rewarding effects of morphine in male F1
offspring, and an increase in reward sensitivity in F1 female offspring. In the present study, we
similarly observed no effect of maternal morphine exposure in F1 males, but in contrast, we did
not observe a difference in F1 female offspring. Differences in the exposure and mating
paradigm, as well as species, may account for the discrepancy between our findings and those of
Vassoler et al. (2016). We found that maternal morphine exposure increases morphine reward in
F2 males and paternal morphine exposure decreases morphine reward in F1 males but increases
it in F1 females. The notion that paternal drug exposure mitigates the response to drugs of abuse
in male offspring has previously been demonstrated with morphine [9], cocaine [19], and alcohol
[20,21].

In the present study, affective behavior was assessed using three tests: marble burying, acoustic
startle response, and open field. We found that maternal morphine exposure did not affect
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affective behavior in F1 or F2 offspring of either sex. However, F1 male offspring from the
paternal morphine exposure spent less time in the center of the open field, which replicates
findings from a previous study in rats [22]. In contrast, F1 female offspring of morphine-exposed
fathers spent more time in the center of the open field. Previous reports in rats have provided
mixed results in the open field test. One group found that morphine exposure in the father,
mother, or both parents resulted in an increase in anxiety-like behavior in the open field (i.e. less
time spent in center) in both male and female F1 offspring [22]. Another group found that
maternal morphine exposure resulted in a decrease in anxiety-like behavior in the open field test
for female F1 offspring; male offspring were not tested [7]. This discrepancy in findings could be
due to the difference in age of the F0 mice when they were exposed to morphine--Li et al. (2014)
exposed parents to morphine during adulthood while Byrnes et al. (2011) exposed parents during
adolescence. In the present study, male and female mice were also exposed during adolescence;
thus, the age at which parental exposure occurs may be important for transmission of alterations
in affective behavior.

There were no differences observed in affective behaviors in F2 males suggesting that unlike
reward, parental exposure to morphine does not result in transgenerational inheritance of altered
affective behaviors. However, F2 females from paternal morphine exposure buried more marbles
in the marble burying task and demonstrated normal behavior in the open field. While the open
field and marble burying assays are both purported to measure anxiety-like behavior [23,24],
these tests have often yielded contradictory results across studies, in part owing to differences in
mouse strains and experimental parameters [25]. It is also possible that these tests interrogate
different aspects of behavior that are controlled by distinct systems. For example, it has
previously been suggested that marble burying may in fact model perseverative or compulsivelike behavior rather than anxiety-like behavior [26,27]. Further, previous work has demonstrated
that effects of parental morphine exposure on behavior in the open field are dependent upon the
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phase of the estrus cycle [7]. Thus, another possible explanation for the present results is that
paternal morphine exposure alters estrogenic modulation of affective behavior, resulting in
greater fluctuations in affective behavior that are observable across multiple generations.

Of interest, in the F0 paternal exposure arm of our study, we observe that F1 males and femalelineage F2 males show decreased reward in the CPP paradigm and increased anxiety-like
phenotypes, while F1 females show increased reward and decreased anxiety-like behavior. The
coincidence of these behavioral phenotypes could reflect altered signaling within the basolateral
amygdala (BLA), which plays a critical role in mediating both anxiety-like behavior and
conditioned aspects of reward [28-30]. Altered histone H3 acetylation in the BLA has been shown
to impact morphine CPP; however, it is not known whether this epigenetic change may be
heritable [31,32].

There are several limitations to this study that warrant discussion. First, differences in the
behavior of morphine-exposed F0 male and female offspring could be influenced by differences in
the age of F0 exposure. F0 males were exposed to morphine during early adolescence
(beginning on PND 28) while females were exposed to morphine during mid-late adolescence
(beginning on PND 42); each phase of adolescence is associated with distinct developmental
changes [33]. Second, we did not control for effects of F0 morphine treatment on maternal care.
A previous study by Johnson et al. (2011) demonstrated that adolescent exposure to morphine in
female mice results in modest differences in maternal care, including reduced nursing frequency
and increased frequency away from the nest during the dark cycle [34]. It is conceivable that
these differences could be transmitted to the F1 generation, impacting maternal care of the F2
offspring as well. In future work, differences in maternal care could be controlled for by crossfostering pups with drug-naïve dams. Finally, we did not include a saline control group in the CPP
experiments, and therefore cannot rule out the possibility that differences in preference scores
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between treatment groups reflect differences in the stability of side preference over time.
However, given that previous studies have found no effect of F0 maternal or paternal morphine
exposure on preference scores amongst saline-conditioned rats, we believe this is unlikely [2,9].

The current study provides evidence for transgenerational inheritance of morphine-induced
behavioral changes. The mechanism by which paternal or maternal exposure to morphine alters
the behavior of offspring is not yet understood. However, others have demonstrated that stress,
toxins, and cocaine alter the germline epigenome through DNA methylation [35-40], histone
acetylation [19], and potential non-coding RNA in the germline [41-43]. In both humans and
animal models, opioid exposure has been shown to increase histone H3 acetylation, which
promotes transcriptional activation, in regions of the brain that play an important role in reward
encoding [32,44,45]; however, it is not known whether this change may be transmissible to future
generations. Given that the mu opioid receptor is expressed in sperm [46], and all opioid receptor
types are expressed in oocytes [47], it is conceivable to hypothesize that morphine exposure
affects the epigenome of gametes and/or gonadal tissue, which is transferred to offspring
resulting in altered behavioral phenotypes.

In future work, it will also be important to examine potential mechanisms underlying the sexspecificity of these behaviors in offspring. In general, we observed stronger behavioral effects in
F1 offspring descended from F0 morphine-exposed males, as compared to the F1 descendants
of F0 morphine-exposed females. This could be the result of sex-specific modulation of
epigenetic influences, which can impact the ability to transmit traits as well as to inherit them
[48,49]. Sex differences in transmission could also reflect differences in the nature of underlying
epigenetic changes. For instance, alterations to sperm RNA have been shown to underlie
transgenerational inheritance of paternal stress and diet-induced obesity [43,50]. Despite a
plethora of important but descriptive studies like this one, our understanding of the mechanism by
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which paternal and maternal morphine exposure affect subsequent generations remains limited.
How initial opioid exposure may impact germline reprogramming, allowing epigenetic marks to be
retained and transmitted from one generation to the next in a lineage-specific manner, will require
novel approaches. Transgenerational epigenetic inheritance also has the potential to be adaptive
and responsive to both external and internal influences leading to divergent behaviors across
sexes and generations.
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Tables
Table A1. Affective behaviors in male lineage offspring of male mice exposed to morphine or
placebo prior to mating. The mean ± SEM for number of marbles buried, time spent in the center
and total distance traveled in the open field, and startle amplitude at 120 dB are presented for F1
male offspring and the F2 males and females from F1 male offspring. *p < 0.05 compared to
placebo controls.
Group

F1 ♂

F2 ♂

F2 ♀

F0 ♂
Placebo
Exposure
6.86 ± 0.98
52.1 ± 6.66
55.0 ± 11.2
36.4 ± 2.07
6.19 ± 0.90
79.2 ± 7.49
31.0 ± 9.38
38.4 ± 2.52
4.30 ± 0.56
66.3 ± 12.2
23.4 ± 5.59
36.3 ± 3.86

Behavior
Marbles buried
Startle Amplitude (120 dB)
Time in Center of OFT (sec)
Total Distance traveled in OFT (m)
Marbles buried
Startle Amplitude (120 dB)
Time in Center of OFT (sec)
Total Distance traveled in OFT (m)
Marbles buried
Startle Amplitude (120 dB)
Time in Center of OFT (sec)
Total Distance traveled in OFT (m)
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n
14
12
17
17
21
10
10
10
20
9
10
10

F0 ♂
Morphine
Exposure
5.00 ± 0.73
48.3 ± 5.66
32.4 ± 3.97*
36.8 ± 1.76
5.43 ± 0.73
74.9 ± 8.89
48.6 ± 12.1
38.2 ± 1.94
5.90 ± 0.81
81.6 ± 16.2
36.2 ± 7.21
40.6 ± 1.58

n
12
10
22
22
21
12
9
9
20
10
10
10

Table A2. Affective behaviors in female lineage offspring of male mice exposed to morphine or
placebo prior to mating. The mean ± SEM for number of marbles buried, time spent in the center
and total distance traveled in the open field, and startle amplitude at 120 dB are presented for F1
female offspring and the F2 males and females from F1 female offspring. *p < 0.05 compared to
placebo controls. #p = 0.08 compared to placebo controls.
Group

F1 ♀

F2 ♂

F2 ♀

F0 ♂
Placebo
Exposure
3.46 ± 1.11
56.4 ± 7.51
28.8 ± 4.51
36.1 ± 1.33
5.96 ± 0.94
72.9 ± 8.15
31.3 ± 6.38
35.2 ± 3.22
6.47 ± 1.17
54.4 ± 11.3
43.6 ± 10.5
37.1 ± 3.44

Behavior
Marbles buried
Startle Amplitude (120 dB)
Time in Center of OFT (sec)
Total Distance traveled in OFT (m)
Marbles buried
Startle Amplitude (120 dB)
Time in Center of OFT (sec)
Total Distance traveled in OFT (m)
Marbles buried
Startle Amplitude (120 dB)
Time in Center of OFT (sec)
Total Distance traveled in OFT (m)
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n
13
14
17
17
23
12
8
8
17
9
8
8

F0 ♂
Morphine
Exposure
3.21 ± 0.73
55.9 ± 8.62
52.9 ± 9.34*
36.4 ± 1.61
8.52 ± 1.10#
62.8 ± 6.75
35.9 ± 7.08
38.3 ± 2.42
9.50 ± 0.87*
62.7 ± 9.33
51.0 ± 7.79
34.8 ± 1.32

n
14
15
16
16
23
13
10
10
22
11
11
11

Table A3. Affective behaviors in male lineage offspring of female mice exposed to morphine or
placebo prior to mating. The mean ± SEM for number of marbles buried, time spent in the center
and total distance traveled in the open field, and startle amplitude at 120 dB are presented for F1
male offspring and the F2 males and females from F1 male offspring. #p = 0.083 compared to
placebo controls.
Group

F1 ♂

F2 ♂

F2 ♀

F0 ♀
Placebo
Exposure
10.1 ± 1.03
90.4 ± 10.9
26.0 ± 4.85
40.3 ± 2.80
4.56 ± 0.68
73.1 ± 7.89
9.31 ± 2.74
33.3 ± 1.72
4.45 ± 0.74
53.2 ± 6.25
18.5 ± 3.98
38.0 ± 1.77

Behavior
Marbles buried
Startle Amplitude (120 dB)
Time in Center of OFT (sec)
Total Distance traveled in OFT (m)
Marbles buried
Startle Amplitude (120 dB)
Time in Center of OFT (sec)
Total Distance traveled in OFT (m)
Marbles buried
Startle Amplitude (120 dB)
Time in Center of OFT (sec)
Total Distance traveled in OFT (m)
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n
12
12
11
11
27
27
24
24
20
20
13
13

F0 ♀
Morphine
Exposure
7.83 ± 1.36
99.4 ± 13.6
25.6 ± 4.63
42.4 ± 1.95
5.17 ± 0.69
89.7 ± 11.6
12.1 ± 4.63
33.2 ± 1.06
4.91 ± 0.93
68.0 ± 6.30
11.5 ± 2.16
33.6 ± 1.65#

n
12
12
12
12
23
23
23
23
21
20
18
18

Table A4. Affective behaviors in female lineage offspring of female mice exposed to morphine or
placebo prior to mating. The mean ± SEM for number of marbles buried, time spent in the center
and total distance traveled in the open field, and startle amplitude at 120 dB are presented for F1
female offspring and the F2 males and females from F1 female offspring.

Group

F1 ♀

F2 ♂

F2 ♀

F0 ♀
Placebo
Exposure
6.64 ± 1.31
73.0 ± 9.55
20.8 ± 2.84
40.4 ± 1.46
7.23 ± 0.76
66.4 ± 6.27
12.1 ± 2.33
35.9 ± 2.39
8.08 ± 0.94
65.9 ± 7.07
13.5 ± 1.85
38.8 ± 1.69

Behavior
Marbles buried
Startle Amplitude (120 dB)
Time in Center of OFT (sec)
Total Distance traveled in OFT (m)
Marbles buried
Startle Amplitude (120 dB)
Time in Center of OFT (sec)
Total Distance traveled in OFT (m)
Marbles buried
Startle Amplitude (120 dB)
Time in Center of OFT (sec)
Total Distance traveled in OFT (m)
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n
14
13
13
13
26
26
25
25
24
25
24
24

F0 ♀
Morphine
Exposure
9.19 ± 0.98
94.9 ± 12.7
31.3 ± 5.41
38.2 ± 1.87
6.08 ± 0.79
77.9 ± 5.41
12.9 ± 1.89
36.7 ± 1.62
7.57 ± 0.87
71.0 ± 5.58
15.7 ± 3.61
36.2 ± 1.62

n
16
16
16
16
25
24
22
22
28
28
27
27

Figures

Figure A1. Paternal morphine exposure affects morphine conditioned place preference in
male offspring. CPP preference scores (mean ± SEM) in F1 males (A) and their F2 male (B) and
female (C) offspring. Striped bars represent mice from the F0 Male Placebo exposure and solid
bars represent F0 Male Morphine exposure groups. *p < 0.05.
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Figure A2. Paternal morphine exposure affects morphine conditioned place preference in
female offspring. CPP preference scores (mean ± SEM) in F1 females (A) and their F2 male (B)
and female (C) offspring. Striped bars represent mice from the F0 Male Placebo exposure and
solid bars represent F0 Male Morphine exposure groups. *p < 0.05.

133

Figure A3. Maternal morphine exposure affects morphine conditioned place preference in
male F2 offspring. CPP scores (mean ± SEM) in F1 males (A) and their F2 male (B) and female
(C) offspring. Striped bars represent mice from the F0 Female Placebo exposure and solid bars
represent F0 Female Morphine exposure groups. *p < 0.05.
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Figure A4. No effect of maternal morphine exposure on morphine conditioned place
preference. CPP preference scores (mean ± SEM) in F1 females (A) and their F2 male (B) and
female (C) offspring. Striped bars represent mice from the F0 Female Placebo exposure and solid
bars represent F0 Female Morphine exposure groups. #p = 0.0563.
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